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CYTOKINES, ANTIBODIES AND PLASMA VIREMIA OF CATS INFECTED WITH 
FELINE IMMUNODEFICIENCY VIRUS 
 
Feline immunodeficiency viruses (FIVs) are naturally occurring lentiviruses (family 
Retroviridae) of felid species, including domestic and wild cats.  Studies on FIVs are beneficial 
for understanding the host immune response associated with disease progression (e.g., domestic 
cat FIV) or the viral kinetics and molecular ecology associated with naturally occurring 
infections in wildlife (e.g., bobcat and mountain lion FIVs).  Here we describe the development 
and validation of the following microsphere immunoassays (MIAs) for evaluating the cytokine 
and antibody response of domestic cats: i) the quantification of cytokines (interferon gamma 
(IFN), interleukin (IL)-10, and IL-12/IL-23) in cell culture supernatant, and ii) the 
quantification of these cytokines in plasma; iii) the quantification of total IgG and IgA in plasma, 
and iv) the detection of IgG and IgA antibodies to feline CD134 (the primary cell receptor for 
FIV), and FIV capsid (CA) and surface (SU) proteins in plasma.  These assays were used to 
evaluate temporal cytokine and antibody responses of domestic cats experimentally infected with 
various FIV strains.  To analyze viral RNA loads associated with naturally occurring FIV 
infections in bobcats or mountain lions, we are adapting existing quantitative PCR assays for use 
with plasma samples.  The eight assays described here are/will be beneficial for addressing 
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CHAPTER 1:  INTRODUCTION 
 
Feline immunodeficiency virus.  Feline immunodeficiency viruses (FIVs) are naturally 
occurring lentiviruses (RNA genome; family Retroviridae) of felids, including at least 10 species 
of free-ranging wild cats (19, 37) and the domestic cat (Felis catus).  The seroprevalence of these 
viruses range from 0-90% (reviewed in (38)), and transmission within a species is thought to 
occur primarily through the exchange of infectious fluids via direct contact (i.e., transfer of 
infectious saliva through bites (3)).  With the exception of domestic cat FIV (FIVFca), these 
viruses are generally thought to be apathogenic in their respective host.  A number of studies 
suggest that African lions (6, 31, 32) and mountain lions (32) may experience pathological 
and/or clinical changes due to FIV infection; however, the association between infection and 
disease is difficult to study in free-ranging felids.  FIVs have many similarities to both human 
and simian immunodeficiency viruses (HIV and SIV), including genomic organization (gag, pol 
and env genes), virion structure, viral replication (including the integration of the FIV DNA 
genome (provirus) into host cell DNA), susceptible target cells and immune response (17, 38).   
Domestic cat feline immunodeficiency virus.  The clinical course of domestic cat FIV 
mimics HIV disease progression, including the hallmark decline of peripheral CD4
+
 T-cells (17, 
27, 46).  Despite a vigorous immune response, FIV and HIV infections are life-long and infected 
individuals eventually succumb to opportunistic infections.  Given the high degree of similarity 
between these two viruses, the domestic cat is an appropriate animal model for evaluating the 
immune response associated with lentiviral infections.  However, a lack of feline-specific 
reagents and/or assays has hampered thorough investigations of the immune response during FIV 
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infection.  Thus, a goal of this research was to develop domestic cat microsphere immunoassays 
to evaluate the cytokine and antibody response of domestic cats infected with FIV. 
Microsphere immunoassays.  Microsphere immunoassay (MIA) technology allows for 
the simultaneous detection of multiple analytes within biological samples (e.g., cytokines, 
chemokines or antibodies; reviewed in (42)).  Multiple sets of microspheres, each with a unique 
ratio of internal dyes and conjugated with a different capture reagent (e.g., antibodies or antigen), 
are combined and incubated with an aliquot of sample (Figure 1.1).  The detection or 
quantification of each analyte is based on the fluorescence intensity of the detection antibody 
reporter dye.  Advantages of MIAs, compared to traditional immunoassays (e.g., enzyme-linked 
immunosorbent assays (ELISAs)), are that less time and sample volume are required.  There are 
commercially available MIA kits for a number of species, including humans, non-human 
primates, horses, pigs, rabbits, dogs, rats and mice; however, no kits are commercially available 
for domestic cats.  Thus, a goal of this research was to develop domestic cat-specific MIAs for 
the quantification or detection of cytokines and antibodies.   
Cytokine response of domestic cats infected with FIV.  Multiple studies have 
evaluated the cytokine response of domestic cats infected with FIV (e.g., (2, 15, 30, 34, 35, 47)).  
Each of these studies examined the mRNA expression of various cytokines, such as interferon 
gamma (IFN), interleukin (IL)-2, IL-6, IL-10, IL-12 and tumor necrosis factor alpha.  Although 
cytokine expression varies by cell type/tissue and time-point examined, the results of these 
studies indicate that cytokine expression during the acute stage of infection may be relevant to 





 T-cells coincided with high tissue viral RNA loads (2), and increased levels 




in FIV  
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Figure 1.1.  Diagram summarizing MIA technology.  Magnetic microspheres (a) have two 
internal dyes, red and infrared (b), which come in varying ratios (regions) assigned by the 
manufacturer.  Multiple analytes can be measured simultaneously within a biological sample by 
coupling different capture reagents to microspheres from spectrally unique regions (i.e., 
chemically activating the carboxyl groups of the surface of the microspheres and forming 
covalent bonds with the primary amines of the capture reagent).  Capture reagents (c) can include 
recombinant viral proteins (yellow) or capture antibodies (dark green).  Once coupled, 
microspheres are first incubated with the sample (e.g., plasma or cell culture supernatant).  If the 
analyte of interest (blue; e.g., antibody or cytokine) is present in the sample, it will bind to the 
capture reagent.  The microspheres are then incubated with detection antibodies.  These 
antibodies can be directly conjugated with the phycoerythrin (PE) reporter molecule (black with 
pink star) or biotinylated (grey with light green square).  If the antibody is biotinylated, the 
microspheres are subsequently incubated with streptavidin-PE (pink star).  The microspheres are 
analyzed on the instrument by individually passing through two lasers (d).  The red laser 
determines the ratio of the two internal dyes of each microsphere (i.e., the microsphere region, 
and therefore analyte) and the green laser determines the intensity of the reporter dye.  The 
instrument samples a well until a designated number of microspheres per region have been 
analyzed (e.g., 100 microspheres).  The data output is median fluorescence intensity (MFI); this 
output can be back calculated to concentration (ng or pg/ml) when standard curves are 
available/generated.  Images obtained from Luminex Corporation (http://www.luminexcorp.com; 
Accessed October 2009 and May 2010). 
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co-infected cats (34).  Since mRNA expression may not necessarily correlate with protein levels 
(i.e., the biologically active form), we sought to develop a multiplex MIA for the quantification 
of feline cytokines using commercially available reagents.   
Cytokine MIAs specific for the domestic cat.  First, we developed and validated a MIA 
for the quantitation of IFN, IL-10 and IL-12/IL-23 in cell culture supernatant (Chapter 2; (44)).  
These three cytokines were selected because a) mRNA expression of these cytokines during the 
acute stage of FIV infection have been evaluated, and differences in the temporal or relative 
expression may be relevant to immunodeficiency pathogenesis (2, 15, 30, 34), and b) reagents 
are commercially available (i.e., from ELISA kits).  Cytokine concentrations of peripheral blood 
mononuclear cell supernatants from naïve and FIV-infected cats were compared between the 
MIA and ELISAs.  The results obtained by the MIA correlated with the values obtained with the 
commercially available ELISAs, indicating that the multiplex assay is a reliable alternative to the 
ELISAs. 
The cell culture supernatant MIA was then modified to quantify IFNγ, IL-10 and IL-
12/23 in domestic cat plasma (Chapter 3; (45)).  Plasma cytokine concentrations were measured 
in two separate in vivo studies, in which domestic cats were infected with apathogenic and/or 
pathogenic FIV ((34), Sprague et al., in preparation; Figure 1.2).  Additionally, the cytokine 
concentrations obtained for one of the in vivo studies (34) were compared to the mRNA cytokine 
expression of blood cells.  IL-12/23 was elevated (p <0.05) in cats inoculated with apathogenic 
and/or pathogenic FIV strains relative to the sham cats during the acute stage of infection (i.e., 
within a month post-infection) in both of the in vivo studies.  IL-12/23 concentrations ranged 
from 377 to 1,904 pg/ml in naïve cats and 552 to 3,460 pg/ml in infected cats.  In contrast, the 
majority of plasma samples had IFNγ and IL-10 concentrations below the lowest standard tested.   
5 
 
Figure 1.2.  Study design for the two in vivo studies, in which domestic cats were infected with 
apathogenic and/or pathogenic FIV ((34), Sprague et al., in preparation). The two virus strains 
used in these studies were FIVPcoB or puma lentivirus-1695 (PLV), a well-characterized viral 
isolate obtained from a British Columbia mountain lion (41), and FIV-C36 (FIV-C), a virulent 
molecular clone of domestic cat FIV that has also been well-characterized (14).  Inoculation of 
domestic cats with PLV results in a productive infection without clinical disease (i.e., 
apathogenic infection) (40).  The 2005 (34) and 2010 (Sprague et al., in preparation) co-infection 
studies included 20 and 24 cats, respectively.  On day -28 of the studies, half of the cats were 
inoculated intravenously (IV) with PLV, and the other half of the cats were sham inoculated.  
Twenty-eight days later (day 0), half of the PLV cats and half of the shams cats were inoculated 
IV with FIV-C, and the remaining cats were sham inoculated.  Cats that were inoculated with 
PLV and FIV-C are referred to as co-infected (CO).   
 
 
The inability to consistently detect levels of IFNγ and IL-10 in plasma, despite the fact that 
mRNA changes were detected, suggests that these cytokines may have different mRNA 
stability/degradation, be secreted and/or cleared in a more highly-regulated manner than IL-
12/23, or perhaps exert local effects under tighter peripheral constraints and/or at a lower 
effective concentration.  
Antibody response of domestic cats infected with FIV.  Domestic cats develop a robust 
antibody response during the early stage of FIV-infection, which consists of both FIV and non-
FIV specific antibodies.  FIV-specific antibodies are detected in plasma/serum within weeks 
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(primarily IgG, but also IgA and IgM (7, 20)) are specific to various viral proteins, including 
capsid (CA), matrix, surface (SU) and transmembrane proteins (16, 20, 22, 26).  In addition, IgG 
antibodies specific to a variety of non-viral and self antigens are also detected after infection 
(18); these antibodies contribute to the elevated levels of total IgG antibodies (1, 20), and are 
thought to be generated due to polyclonal B-cell activation.   
Despite the robust FIV-specific antibody response, domestic cats are unable to eliminate 
the viral infection; however, these antibodies may be beneficial during the later stage of disease.  
For example, over time antibodies to the SU protein are capable of virus neutralization (23), and 
as observed with HIV, the presence of antibodies to the CA/Gag protein correlates with delayed 
disease progression (4, 10, 11, 24, 43).  Additionally, FIV-infected cats that develop 
autoantibodies to CD134 (the primary cell receptor for FIV (12, 33)), tend to have lower peak 
viral loads and less virulent disease than cats that do not develop anti-receptor antibodies (21).  
Grant et al. (21) demonstrated the α-CD134 antibodies bind to a cryptic epitope on the CD134 
receptor, which is only exposed once the virus SU protein is bound (13), and this binding results 
in the displacement of SU from the cell receptor (21).  By blocking viral entry into a cell, these 
results suggest that α-CD134 antibodies directly contributed to the observed reduction in viral 
loads.  Although there are a number of studies that have evaluated the antibody response of FIV-
infected domestic cats (1, 7, 8, 16, 18, 20-22, 26, 28, 29), there are limited data on the 
development of both total and FIV-specific IgG and IgA antibodies during the early stage of 
infection. 
Antibody MIAs specific for the domestic cat.  We developed and validated MIAs for a) 
the quantification of total IgG and IgA levels in plasma, and b) detecting IgG and IgA antibodies 
to feline CD134, and FIV CA and SU proteins in plasma (Chapter 4).  These four assays were 
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then used to examine the temporal antibody response of domestic cats infected with apathogenic 
and pathogenic FIVs (34), and domestic cats infected with parental and chimeric FIVs of varying 
pathogenicity (36).  The goals of these experiments were to determine whether the kinetics 
and/or level of the antibody response is related to virus strain/clinical outcome and/or viral load, 
as well as to estimate the percentage of total IgG antibodies that are CA- or SU-specific.  The 
results from these studies demonstrated that a) total IgG antibodies increase over time after 
infection; b) α-CA and α-SU IgG antibodies are first detectable between 9-28 days post-infection 
and increase over time, and that these antibodies represent a fraction of the total IgG increase; c) 
α-CD134 IgG antibody production varies among individuals and over time, and was not strongly 
correlated with viral load during the early stage of infection; d) circulating IgA antibodies, in 
general, do not increase after intravenous FIV infection; and e) total IgG, and α-CA and α-SU 
IgG antibody kinetics and level vary with FIV viral strain/pathogenicity.  
Puma lentiviruses.  Although FIVs are generally species-specific, mountain lions (Puma 
concolor; also referred to as cougar, panther or puma) can be infected with two distinct FIV 
strains ((19), Lee et al., unpublished).  Throughout North and South America, free-ranging and 
captive mountain lions are infected with FIVPcoB or puma lentivirus (PLV)-B ((9, 19), Lee et al., 
unpublished).  In California and Florida, free-ranging mountain lions are infected with FIVPcoA 
or PLV-A, which is highly divergent from PLV-B ((9, 19), Lee et al., unpublished).  Bobcats 
(Lynx rufus) in California and Florida are also infected with PLV-A, and to-date PLV-A is the 
only FIV sequenced from this species of cat ((19, 25), Lagana et al., in press and Lee et al., 
unpublished).  Given that PLV-A is the only known FIV to infect bobcats and that PLV-A is less 
common in mountain lions than PLV-B, Franklin and Troyer et al. (19) hypothesized that PLV-A 
may actually be of bobcat origin and that PLV-A in the mountain lion is the result of cross-
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species transmission events.  Analyses of PLV-A proviral sequences from pumas and bobcats 
support this hypothesis, in that viral isolates from mountain lions were more likely to be 
undergoing positive selection than bobcat viral isolates (Lee et al., unpublished).  Additional 
support for this hypothesis could be provided by plasma viremia data; previous cross-species 
infection studies with the domestic cat indicate that non-host adapted FIVs (e.g., PLV-A, PLV-B 
or lion lentivirus (FIVPle)) typically result in lower levels of plasma viremia than host-adapted 
FIV strains (39, 40).  
Puma lentivirus quantitative PCR.  PLV-specific primers and plasmids have been 
developed for the quantification of proviral loads in whole blood samples from bobcats and 
mountain lions (Templin-Hladky et al., unpublished).  We are in the process of adapting these 
assays for the quantification of PLV-A and PLV-B RNA in plasma (Chapter 5); these assays will 
be useful for the detection of active viral replication (versus a residual infection indicated by the 
detection provirus).  Experiments have been conducted to determine the linear range of the 
standards and to optimize assay conditions, as well as testing plasma samples from PLV positive 
bobcats and mountain lions (based on provirus sequence data; Lee et al., unpublished).  Of the 
samples tested to-date, only 4 (of 14) of the PLV-B mountain lion samples had viral loads within 




 copies/reaction); these four values are at the low end 
of those previously reported for PLV-B infected mountain lions (5).  All of the PLV-A bobcat 





copies/reaction).  Future experiments will be conducted to concentrate viral RNA and/or cDNA, 
so that the sample concentrations are within the quantifiable range.  Once assay development and 
validation are complete, plasma samples will be tested to determine whether mountain lion  
9 
PLV-A viremia is lower than bobcat PLV-A and mountain lion PLV-B viremia, which would 
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CHAPTER 2:  DEVELOPMENT AND VALIDATION OF A MULTIPLEX 






Cytokines are small proteins secreted by cells to coordinate cellular communication in 
response to inflammation or infection.  As such, these molecules have important roles in innate 
immune responses during an infection and contribute to the activation of the adaptive immune 
response (reviewed in (13)).  Therefore, characterization of the cytokine response is crucial for 
understanding host-pathogen dynamics.  Because cytokines are often secreted in small amounts 
locally and may have short half-lives, detection of cytokines during disease processes has not 
been routinely performed; however, new technologies that allow cytokine detection, either 
during disease states in hosts or in tissue culture systems, would provide additional tools for 
understanding immune modulation.   
Frequently, cytokines are assessed by quantitative PCR (qPCR) or by enzyme-linked 
immunosorbent assay (ELISA); however, both of these methods have limitations (reviewed in 
(19, 20)).  Although qPCR assays can be developed to detect multiple cytokines simultaneously, 
relative mRNA expression may not correlate with protein levels.  ELISAs, on the other hand, 
have the capability to quantify protein, but only one cytokine can be detected in a single ELISA 
assay.  Additionally, these assays are labor-intensive and require a significant sample volume.  
The latter is of particular importance with laboratory animals because of the limited sample 
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volume (e.g., serum, plasma or peripheral blood mononuclear cells (PBMC)) that can be safely 
obtained. 
Microsphere-based assays are a relatively new technology capable of detecting multiple 
analytes simultaneously (reviewed in (9, 20)).  Microspheres with spectrally unique internal dyes 
act as the solid support for individual immunoassays.  Using flow cytometry technology, the 
analyte concentration is determined by the fluorescence intensity of the reporter dye.  Currently, 
there are 100 spectrally unique microspheres available; theoretically, 100 different analytes could 
be detected in a single sample.  There are commercially available cytokine-multiplex kits for 
humans, non-human primates, mice, rats and dogs; however, no kits are currently available for 
domestic cats.  The availability of human and mouse reagents has allowed the analysis of 
cytokine levels in a variety of disease states, including sickle cell disease (1), sepsis (5), viral 
infection in humans (8), and bacterial pneumonia in mice (6).  The capacity to accurately and 
reproducibly evaluate cytokine profiles in domestic cats, in both naturally occurring and 
experimentally induced disease states, would potentially provide valuable information regarding 
disease pathogenesis, progression, and prognosis. 
The purpose of this study was to develop a microsphere-based immunoassay for the 
simultaneous quantitation of the feline cytokines interferon gamma (IFN), interleukin-10 (IL-
10) and IL-12/IL-23 p40 (subsequently referred to as IL-12/23).  These cytokines were selected 
because their mRNA expression during the acute stage of feline immunodeficiency virus (FIV) 
infection has been evaluated and differences in temporal or relative expression may be relevant 
to immunodeficiency pathogenesis (2, 7, 15).  IFN and IL-12 are critical for the differentiation 
of T-helper 1 (Th1) cells, while IFN- is critical for the activation of cytotoxic T lymphocytes 
(CTLs).  CTLs are an important component of the host defense against viral pathogens.  IL-10, 
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on the other hand, is a suppressor of a Th1 immune response.  Our laboratory intends to apply 
this technology to evaluate cytokine profiles of domestic cats during infection with FIV, a 
naturally occurring feline virus with many parallels to human immunodeficiency virus (HIV) 
(14, 16).  Measurements of cytokines secreted from cells in culture following experimental 
infections with different FIV strains could offer new insights into disease pathogenesis and 
progression.  This assay could also be used to study other feline diseases with human 
applications, such as cancer and inflammatory diseases.   
MATERIALS AND METHODS 
Capture antibody coupling to microspheres.  Carboxylated magnetic microspheres 
(Luminex Corporation, Austin, TX) were conjugated with feline IFN, IL-10, and IL-12/23 
capture antibody from DuoSet
®
 ELISA Development kits (R&D Systems, Minneapolis, MN) 
according to the manufacturer’s recommendations for two-step carbodiimide coupling of protein 
to MagPlex-C magnetic carboxylated microspheres (Luminex; Table 2.1).  Briefly, lyophilized 
capture antibody was re-suspended in 1 ml of sterile phosphate-buffered saline (PBS).  Magnetic 
microspheres were washed with 100 μl of distilled water and re-suspended in 80 μl of activation 
buffer (0.1 M sodium phosphate monobasic, anhydrous, pH 6.2).  Carboxyl groups on the 
surface of the microspheres were chemically activated using 10 μl N-hydroxysulfosuccinimide 
(50 mg/ml) and 10 μl 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (50 mg/ml) 
(Fisher Scientific, Pittsburgh, PA).  Activated microspheres were washed twice with 250 μl of 
coupling buffer (0.05 M 2(N-morpholino)ethanesulfonic acid, pH 5.0) and then re-suspended in 
100 μl of the buffer.  Capture antibody was added, and the final volume was brought to 500 μl 
with coupling buffer.  The mixture was incubated for 2 h at room temperature in the dark with 
gentle rotation.  After incubation, coupled microspheres were washed three times (500 μl and  
17 





Analyte Microsphere region Capture antibody Detection antibody Standard 
Feline IFNγ 15 Goat anti-feline IFNγ Biotinylated goat anti-feline IFNγ Recombinant feline IFNγ 
Feline IL-10 33 Mouse anti-feline IL-10 Biotinylated goat anti-feline IL-10 Recombinant feline IL-10 




The analyte, capture antibody, detection antibody and standard were from the DuoSet
®
 ELISA (R&D Systems).  The microsphere 
region (MagPlex-C Microspheres; Luminex) was assigned by manufacturer based on ratio of two internal dyes.  
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two 1-ml washes) with blocking/storage buffer (PBS, 0.1% bovine serum albumin (BSA), 0.02% 
Tween 20, 0.05% azide, pH 7.4).  The microspheres were then re-suspended in blocking/storage 
buffer (150 μl per 10
6
 microspheres) and stored at 4°C in the dark for 2 to 4 months.  
Microsphere concentrations were determined using an automated counter (Invitrogen, Carlsbad, 
CA).   
To confirm antibody coupling, microspheres (~5,000) were incubated with a 
phycoerythrin (PE)-labeled secondary antibody (R&D Systems) according to the manufacturer’s 
recommendations (Bio-Plex amine coupling kit instruction manual: protein coupling validation 
(Bio-Rad, Hercules, CA)).  A median fluorescent intensity (MFI) of  >2,000 indicated successful 
coupling. 
Microsphere assay protocol.  The immunoassay protocol used in these experiments was 
modified from a protocol for a washed capture sandwich immunoassay using magnetic 
microspheres (Luminex).  Aliquots of coupled microspheres were combined in assay buffer 
(PBS, 1% BSA, pH 7.4) for a final concentration of either 50 or 100 microspheres/μl per analyte.  
A 50-μl aliquot of the multiplex microsphere solution (i.e., 2,500 or 5,000 microspheres/analyte 
per well) was then added to each well in a 96-well, round-bottom polystyrene plate (Fisher 
Scientific).  Wells were washed twice with 100 μl of assay buffer using a 96-well magnetic 
separator (Ambion, Austin, TX) and again, after each subsequent incubation.  Plates were 
incubated for 30 min at ~800 rpm in the dark at room temperature.  Microspheres were incubated 
in 50 μl of solution in the following order: (i) sample, standard, spike or cell culture medium 
control (5 to 20% heat-inactivated fetal bovine serum, 2% glutamine, 0.5% 2-mercapto ethanol, 
1% penicillin-streptomycin, quantity sufficient (q.s.) RPMI 1640); (ii) detection antibody; and 
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(iii) streptavidin-PE (Invitrogen).  After the final incubation and washes, the microspheres were 
re-suspended in 100 μl of assay buffer and analyzed. 
A Bio-Plex™ 200 instrument (Bio-Rad) was calibrated before each analysis and 
validated monthly to ensure optimal performance of optics, reporters, fluidics, and classification 
per the manufacturer’s recommendations.  Each plate included an eight-point standard curve  
(2-fold dilution series) and four control wells, in addition to samples with known or unknown 
analyte concentrations.  All standards and samples were run in duplicate.  Median fluorescence 
intensity was calculated from 100 microspheres per analyte per well.  Bio-Plex™ Manager 5.0 
(Bio-Rad) was used for data collection and analysis.  A five-parameter logistic standard curve 
was generated for each analyte from the standards by plotting concentration versus fluorescence.  
The computer program calculated the concentration of each sample or spike using the respective 
analyte standard curve.  Acceptable standard recovery was 70 to130% of the nominal value (Bio-
Plex cytokine assay instruction manual; Bio-Rad). 
Microsphere assay development.  Assay development and optimization were conducted 
in the following order:  (i) optimization of capture antibody concentrations, (ii) optimization of 
detection antibody concentrations, (iii) determination of standard curve ranges, (iv) evaluation of 
cross-reactivity among analytes, (v) comparison of MFI between single and multiplex standard 
curves, (vi) optimization of streptavidin-PE concentration, and (vii) optimization of the number 
of microspheres per well.  Capture antibody concentrations tested were 1, 2.5, 5, 7.5, 10, and 15 
g per 10
6
 microspheres.  Detection antibody concentrations tested were 1X, 2X,and 3X the 
recommended concentration for ELISA protocols.  Standard curve ranges evaluated were based 
upon the recommendations of the ELISA protocols (7-point curves), with three additional lower 
concentrations (i.e., a 10-point curve was tested).  To test for cross-reactivity among analytes, 
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each cytokine standard curve was individually tested with multiplex microspheres and detection 
antibody.  Additionally, to determine if the MFI was affected by multiplexing analytes, single 
and multiplex standard curves were compared.  Streptavidin-PE concentrations tested were 2, 3, 
and 4 g/ml.  The number of microspheres tested per well were approximately 1,000, 2,000, 
2,500, and 5,000 microspheres per analyte to determine the minimum number required per well.   
Multiplex assay validation.  Intra- and inter-assay experiments were conducted to 
determine both the accuracy and precision of the multiplex assay.  In these experiments, the 
spike concentrations tested were based upon the dilution series of the standard curve.  The stock 
solution of each standard provided by the ELISA kit manufacturer was diluted to three 
concentrations and spiked into cell culture medium to test the accuracy of detecting sample 
concentrations based upon the standard curves generated.  Spike concentrations were as follows: 
31, 250, and 1,000 pg/ml for IFN; 63, 500, and 2,000 pg/ml for IL-10; and 39, 156, and 625 
pg/ml for IL-12/23.  For the intra-assay experiment, 10 wells with each spike concentration were 
run in a single experiment.  For the inter-assay experiments, spiked samples (duplicate or 
quadruplicate wells) were run in nine separate experiments. 
Acceptable spike recovery was 70 to130% of the nominal value (Assay qualification 
guidelines for Luminex assays; Panomics, Santa Clara, CA).  The coefficient of variation (CV) 
for the mean spike recoveries at each concentration was required to be <20% for the intra-
assay experiment and <30% for the inter-assay experiments (Bio-Rad, personal 
communication).  The lower limit of quantitation (LLOQ) was the lowest concentration tested 
that was repeatedly recovered.  The upper limit of quantitation (ULOQ) was the highest 
concentration tested that was repeatedly recovered.  
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Generation of supernatant from domestic cat PBMC.  We compared cytokine values 
determined by commercially available, unvalidated ELISAs (DuoSet
®
 ELISA Development kits; 
R&D Systems) to those determined by the multiplex assay using cell culture supernatant samples 
generated from domestic cat PBMC.  The ELISA kits are marketed as a reagent resource for 
analysis of cytokines in cell culture supernatant.  Cell culture supernatant samples generated in 
our laboratory were tested to verify that the multiplex assay was capable of detecting natural 
cytokines produced by domestic cat cells (i.e., other than the recombinant cytokines standards).  
Specific-pathogen-free domestic cats were housed in Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC, Intl.) approved facilities and 
handled under protocols approved by the Colorado State University Institutional Animal Care 
and Use Committee (IACUC).  Heparinized blood was collected from both naïve and FIV-
positive cats sedated with ketamine-acepromazine.  PBMC were isolated using a Histopaque 
gradient (Sigma-Aldrich, St. Louis, MO) and re-suspended in medium.  Cells were grown in the 
presence of 0, 0.5, or 5 g/ml of concanavalin A (ConA) (Sigma-Aldrich).  Additionally, 
PBMCs from naïve cats were infected in vitro with one of two FIV strains, as a component of 
other ongoing experiments.  Supernatants were harvested from 1 to 10 days post-culture and 
stored in aliquots of 0.5 to 1 ml at -80°C until tested with both assays.   
ELISA and multiplex cytokine analysis of supernatant samples.  The manufacturer’s 
protocol was followed for each ELISA, although the standard curve range was altered to reflect 
the range used in the microsphere assay.  IFN, IL-10, and IL-12/23 concentrations in all 
samples were tested simultaneously by both assays to minimize freeze-thaw and sample storage 
variability.  Samples were included in the assay comparison analysis if the concentrations 
obtained from both assays were within the standard range tested (i.e., a sample was excluded if 
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one or both assays resulted in a concentration above or below the standard range).  Values were 
compared using a Spearman’s rank correlation for nonparametric data and 95% prediction 
intervals (GraphPad Prism 5.0; GraphPad, La Jolla, CA).   
RESULTS 
Microsphere assay conditions.  Each component of the microsphere assay was tested 
individually.  The findings from these experiments (summarized in Table 2.2) are as follows.   
 













(per region per well) 
IFNγ 5 2,400 3 2,500 
IL-10 5 200 3 2,500 
IL-12/23 5 300 3 2,500 
 
 
 (i) Capture antibody concentration.  The optimal concentration was the highest point 
in the linear range (i.e., before saturation).  Five micrograms of capture antibody 
per 10
6
 microspheres was found to be the optimal concentration for microsphere 
coupling for each analyte.   
(ii) Detection antibody concentration.  Concentrations that resulted in MFIs of >2,000 
for a high standard and <100 for a low standard were selected.  For IL-10, the 
concentration of detection antibody that met these criteria was the same as the 
concentration recommended in the ELISA protocol (200 ng/ml).  For IFN and 
IL-12/23, the concentrations that met these criteria was 3X the recommended 
ELISA concentrations (2.4 g/ml and 300 ng/ml, respectively).  Detection 
antibody saturation was not determined.   
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(iii) Standard curve range.  All 10 tested concentrations were detected for each 
analyte (Table 2.3).  The lowest concentration (8 pg/ml for IFN, 16 pg/ml for IL-
10, and 5 pg/ml for IL-12/23) was eliminated from future standard curves because 
the MFI was only slightly higher than that of unspiked controls.  The highest 
concentration (4,000 pg/ml for IFN, 8,000 pg/ml for IL-10, and 2,500 pg/ml for 
IL-12/23) was also eliminated because this was above the expected concentration 
for cell culture supernatant samples.   
 
Table 2.3. Standardized range for each analyte using the microsphere assay compared to the 
recommended standard range for the ELISAs. 
 
 
Assay and  pg/ml  
parameter IFNγ IL-10 IL-12/23 
ELISA    
     Standard curve 63-4,000 125-8,000 39-2,500 
    
Microsphere assay    
     Standard range tested 8-4,000 16-8,000 5-2,500 
     Standard curve 16-2,000 31-4,000 10-1,250 
     LLOQ 31 63 39 
     ULOQ 1,000 2,000 625 
 
 
 (iv) Testing for cross-reactivity among analytes.  Minimal cross-reactivity was 
observed among analytes; values ranged from 3-34 MFI.   
(v) Comparison of MFI between single and multiplex standard curves.  Each analyte 
had only minor differences between single and multiplex standard curves (Figure 
2.1), indicating that these analytes could be analyzed in multiplex format.    
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(vi) Streptavidin-PE concentration.  The streptavidin-PE concentration used up to this 
stage of the optimization process (i to v) was 4 g/ml as per the microsphere 
manufacturer’s recommendations.  All standards were detectable when the 
concentration of streptavidin-PE was decreased to 3 g/ml.  The lowest 
concentration of the IL-12/23 standard curve was not detected when the 
streptavidin-PE concentration was decreased to 2 g/ml; therefore, 3 g/ml was 
used for all further experiments.   
(vii) Microsphere concentration.  The microsphere input per well for each analyte used 
throughout the optimization process (i to vi) was 5,000 as per the microsphere 
manufacturer’s recommendations.  Standard concentrations and microsphere 
readings were unaffected by decreasing the microsphere input to 2,500 per analyte 
(i.e., the minimum of 100 microspheres were read for each analyte).  Decreasing 
the microsphere input to 2,000 per well or below did not always result in the 
reading of 100 microspheres; therefore, we determined 2,500 to be the lower limit 
for assay reproducibility.   
Multiplex assay validation.  For all three analytes, the individual spike concentration 
recoveries (accuracy) were within the manufacturer-recommended acceptable range of 70 to 
130%.  The mean recoveries for each analyte at each concentration for the inter- and intra-assay 
experiments were within these limits (Table 2.4).  Precision was measured as the percent CV of 
the individual recoveries for spikes at each concentration per analyte.  All of the percent CVs for 
the inter- and intra-assay experiments were also within the validation requirements 
recommended by the manufacturer (<20% in the intra-assay and <30% in the inter-assay 
experiments; Table 2.4). 
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and spike level 
         Mean % recovery (% CV) 
IFNγ IL-10 IL-12/23 
Intra-assay    
     High 120 (5) 106 (4) 114 (4) 
     Medium 120 (4) 99(13) 116 (4) 
     Low 109 (11) 95 (7) 110 (10) 
    
Inter-assay    
     High 105 (5) 107 (8) 108 (5) 
     Medium 109 (5) 107 (6) 111 (5) 
     Low 103 (16) 109 (8) 112 (9) 
 
 
The validated limits of quantitation per analyte are summarized in Table 2.3.  The lowest 
standard used for each analyte in the microsphere assay is one-fourth the concentration of the 
lowest standard recommended for each ELISA protocol.   
Comparison to commercially available ELISAs.  The number of supernatant samples 
in which cytokine concentrations were quantifiable by both ELISA and the microsphere assay 
varied for each analyte (Figure 2.2) (n = 24 for IFN, n = 38 for IL-10, and n = 27 for IL-12/23).  
The Spearman rank correlation (Rs) was 0.79 for IFN, 0.93 for IL-10, and 0.86 for IL-12/23.  
The values indicate a positive linear relationship between cytokine concentrations obtained by 
ELISA and by the multiplex microsphere assay. Most data fell within the 95% prediction interval 
(Figure 2.2), further demonstrating high correlation between the assays. 
DISCUSSION 
This study demonstrates the successful development and validation of a microsphere-
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Figure 2.2.  Cytokine concentrations in domestic cat PBMC samples measured by ELISA and 
the microsphere assay are correlated.  (a) IFN; (b) IL-10; (c) IL-12/23.  Dashed lines represent 






IL-12/23.  To our knowledge, this is the first microsphere-based assay developed for the 
domestic cat.  
The microsphere assay has several advantages over commercially available ELISAs.  The 
time required for the microsphere assay is less than the time required for the three ELISAs, and 
the microsphere assay is much simpler to conduct.  The microsphere assay detects lower 
concentrations of the analytes than the standard ranges recommended by the ELISA protocols 
(Table 2.3).  Additionally, the microsphere assay requires only 50 μl of sample for analysis, 
compared to 300 μl of sample required for performing the three corresponding cytokine ELISAs.  
Finally, the microsphere assay has been optimized and validated using industry-recommended 
requirements, ensuring reproducible quantification of cytokine values both within and among 
experiments. 
The true quantifiable range of each cytokine is likely broader than the range tested (i.e., 
the true ULOQ is likely higher and the true LLOQ is likely lower than the concentrations tested 
in this assay). The high spikes had the same concentration as the second-highest standard, 
whereas the low spikes had the same concentration as either the second- or third-lowest standard.  
Although the true ULOQs of the assay were not reached, the majority of the cell culture 
supernatant samples for each analyte were below the high spike concentration.  This is 
demonstrated in Figure 2.2 by detectable levels of cytokines in PBMC cultures; most 
concentrations were detected in the lower 30 to 50% of the standard range. The highest values 
tended to occur in supernatants from PBMC stimulated with high concentrations of a ConA, a 
potent T-cell mitogen. 
Cytokine concentrations of biologically relevant samples in the microsphere assay and 
ELISAs were compared.  Since the ELISAs were not validated, we cannot state with certainty 
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that the absolute values obtained by both assays are equivalent; however, correlation analysis 
does demonstrate that values were proportionate and fell within the 95% predictive limits for the 
vast majority of data points.  This analysis indicates that the multiplex assay has been properly 
established to predict cytokine concentrations in samples and that these values would be similar 
to those obtained with the commercially available ELISAs. 
During intra- and inter-assay validation, it was noted that fluorescence decreased across 
the plate (i.e., MFI was higher in the first samples read and the values decreased over time), 
though recoveries were still within the acceptable range.  Experiments conducted after assay 
validation revealed that re-suspension of microspheres in a 0.1% formalin solution before 
analysis decreased MFI drift (10, 12); see Technology tips: stop solution or fixative [Luminex]).   
It is possible that the accuracy and precision of the validation experiments would have improved 
if this fixation step had been included; however, the values reported here are similar to those 
reported for other assays with (10) and without (4, 11) fixation.  We therefore recommend that a 
formalin fixation step be considered as a component of cytokine multiplex procedures to 
stabilize MFI and to increase assay accuracy and precision. 
Microsphere-based assay development has expanded the number of analytes that can be 
simultaneously detected in biological samples (e.g., cytokines, antigens, and antibodies).  
Commercially available cytokine kits and assays developed by individual research groups (e.g., 
for porcine [(4)] and horse (21)] cytokines) provided valuable insights into the innate immune 
response of a host against infection.  For example, microsphere-based assays have been used to 
characterize the cytokine response in the lymph nodes of chronically infected HIV patients (3) 
and cytokine production during acute HIV-1 infections (17).  Both studies demonstrate 
quantifiable differences in cytokine levels between HIV-infected tissues/patients and 
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control/comparison groups.  These differences stress the importance of characterizing the innate 
immune response in HIV infections in order to gain insights into future vaccine and drug 
development.  Additionally, in a translational study for human acute lung injury (ALI), 
investigators characterized the cytokine response of canines with induced ALI and the effect of 
sphingosine 1-phosphate (S1P) treatment (18).  Although there was variation in cytokine 
production and S1P was found to reduce lung injury, this appeared to be independent of the 
cytokine response.  We speculate that the domestic cat cytokine assay described here may have 
both experimental and clinical applications for defining disease states.   
In summary, this study describes an optimized and validated assay for the simultaneous 
quantification of three domestic cat cytokines in a convenient and reproducible platform.  
Commercially available reagents that could be used to expand this panel for the detection of 
additional cytokines include those for IL-1, IL-2, IL-4, IL-6, and/or tumor necrosis factor alpha, 
adding to the utility of this assay.  Further efforts will be directed toward the development of a 
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CHAPTER 3:  MICROSPHERE IMMUNOASSAY FOR THE DETECTION OF 
CYTOKINES IN DOMESTIC CAT (FELIS CATUS) PLASMA: ELEVATED IL-12/23 IN 





Microsphere immunoassays (MIAs) are a relatively new technology capable of detecting 
multiple analytes simultaneously (reviewed in (7)).  Microspheres with spectrally unique internal 
dyes act as the solid support for individual immunoassays.  Using flow cytometry technology, 
the analyte concentration is determined by the fluorescence intensity of the reporter dye.  MIA 
kits are commercially available for the quantification of various analytes, including cytokines, 
soluble cytokine receptors, chemokines and antibodies.  These kits are available for humans, 
non-human primates, dogs, mice and rats; however, no kits are commercially available for the 
domestic cat.   
Feline immunodeficiency virus is a naturally occurring lentivirus of the domestic cat 
(FIVFca, subsequently referred to as FIV) that is similar to human immunodeficiency virus (HIV) 
in terms of viral structure, transmission, target cells and disease progression (5, 10, 20).  Clinical 
disease is characterized by flu-like symptoms and a decrease in CD4
+
 T-cells during the acute 
stage of infection, followed by a long asymptomatic stage in which CD4
+
 T-cells continually 
decline (reviewed in (5)).  Despite a vigorous immune response, FIV and HIV infections are life-
long and infected individuals succumb to opportunistic infections.  Given the high degree of 
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similarity between FIV and HIV, the domestic cat is an appropriate animal model for evaluating 
the relationship between CD4
+
 T-cell depletion and immune activation with lentiviral infections. 
 Inoculation of domestic cats with FIVPco (subsequently referred to as PLV), a lentivirus 
native to the mountain lion and genetically related to domestic cat FIV (2), causes productive 
infection without clinical disease (15).  PLV proviral loads decrease in peripheral blood 
mononuclear cells (PBMC) within three months of infection, and are higher in the 
gastrointestinal tract than lymphoid tissues (13).  Previous studies conducted by our laboratory 
demonstrate that PLV infection before FIV infection (i.e., co-infection) blunts the peripheral 
CD4
+
 T-cell loss observed during the acute phase of FIV single-infection (12, 14).  The 
mechanism(s) underlying this peripheral CD4
+
 T-cell maintenance is still under investigation, 
including the host cytokine response.  
Here we a) describe the development and validation of a MIA to simultaneously quantify 
domestic cat cytokines interferon gamma (IFN), interleukin (IL)-10, and IL-12/IL-23 p40 (IL-
12/23) in plasma (modified from (18)), b) demonstrate the use of this assay with plasma samples 
collected from domestic cats inoculated with FIV and/or PLV, and c) compare cytokine 
concentrations to mRNA expression.  IFN, IL-10, and IL-12/23 were selected because reagents 
are commercially available, and their mRNA expression during the acute stage of infection may 
be relevant to immunodeficiency virus pathogenesis (1, 4, 11, 12). 
MATERIALS AND METHODS 
Antibodies and standards.  Capture and detection antibodies specific for domestic cat 
cytokines, and recombinant cytokine standards were obtained from DuoSet
®
 Enzyme-linked 
Immunosorbent Assay (ELISA) Development kits (R&D Systems, Minneapolis, MN).  The 
reagents used in the IL-10 and IFN sandwich ELISAs detect both monomers and homodimers 
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of their respective molecules (personal communication, R&D Systems).  IL-12 and IL-23 are 
heterodimers, which share a common p40 subunit.  The sandwich ELISA detects p40 monomers 
and heterodimers of IL-12 and IL-23 (kit insert, R&D Systems). 
Coupling capture antibody to microspheres.  Methods for coupling capture antibody to 
microspheres and confirmation of coupling are identical to those previously described (18), with 
the exception that microsphere concentrations were determined using a hemocytometer.  For 
each analyte, the concentration of capture antibody used was 5 g per 10
6
 microspheres (optimal 
concentration reported in (18)). 
Plasma sample dilution and standard diluent.  Plasma is a complex matrix, which 
includes endogenous and exogenous components (e.g., complement, rheumatoid factors, 
autoantibodies and anticoagulants) that can cause bias in immunoassays and result in inaccurate 
quantification of the analytes of interest (reviewed in (9, 19)).  Bias can also be attributed to 
differences between the matrices of samples and standards (17), and can affect the measurement 
of individual cytokines differently (6).  To reduce the effect of the sample matrix on cytokine 
concentrations, plasma samples were diluted 1-in-5 (as per the microsphere manufacturer’s 
recommendations) in phosphate-buffered saline (PBS).  Although this dilution reduced the effect 
of the matrix on cytokine detection, the limits of quantitation (see below) increased by a factor of 
five (i.e., the 1-in-5 dilution reduced the sensitivity of the assay).  
To minimize any differences between sample and standard matrices, we initially diluted 
standards in PBS + 20% pooled naïve domestic cat sera (Colorado State University specific-
pathogen free cat colony; equivalent to 1-in-5 sample dilution).  However, background levels of 
IL-12/23 present in naïve cat sera affected the accuracy of the IL-12/23 standard curve at low 
concentrations.  Alternative sera were tested, including donkey and feline (Jackson 
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ImmunoResearch Laboratories, West Grove, PA), fetal bovine (Atlanta Biologicals, 
Lawrenceville, GA), goat (MP Biomedicals, Solon, OH) and mouse (Invitrogen, Carlsbad, CA), 
as well as human standard diluent (Bio-Rad, Hercules, CA).  Of these reagents, PBS + 20% goat 
sera was the only diluent in which all eight-points of the standard curve for each analyte were 
detectable and where there was no cross-reactivity of factors in the sera with feline antibodies.  
Microsphere immunoassay protocol.  The MIA protocol used was similar to the 
method described in Wood et al. (2011), with the following modifications: standards and spikes 
were prepared in PBS + 20% goat serum, diluent controls (blanks) consisted of PBS + 20% goat 
sera, and after the final wash microspheres were re-suspended in 100 μl of 0.5% formaldehyde 
(37% w/w; Fisher Scientific, Pittsburgh, PA) in assay buffer.  Spikes (samples of known 
concentration) were prepared similar to the standards and used for assay validation.  Spikes were 
also interspersed throughout the plate (i.e., beginning, middle and end) as additional controls 
during analysis of plasma samples.  Approximately 2,500 microspheres per analyte were added 
to each well and plasma samples were diluted 1-in-5 with PBS.  Each experiment included an 
eight-point standard curve (2-fold dilution series) and four diluent control wells.  
Bio-Plex
™
 200 (Bio-Rad) maintenance and data analysis (Bio-Plex
™
 Manager 5.0, Bio-
Rad) were identical to the methods previously described (18).  Briefly, median fluorescence 
intensity (MFI) was calculated from 100 microspheres per analyte per well.  For each analyte, a 
standard curve was generated and used to calculate cytokine concentrations in spikes and plasma 
samples.  Acceptable standard recovery was 70-130% of the nominal value (Bio-Rad).   
Microsphere immunoassay validation.  Inter- and intra-assay experiments were 
conducted as previously described (18).  Spike concentrations were: 31, 250 and 1,000 pg/ml for 
IFN; 63, 500 and 2,000 pg/ml for IL-10; and 20, 156 and 625 pg/ml for IL-12/23.  Acceptable 
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accuracy (spike recovery) was 70-130% of the nominal value (Panomics, Santa Clara, CA), and 
acceptable precision (coefficient of variation (CV)) for the mean spike recovery at each 
concentration was required to be <20% for the intra-assay and <30% for the inter-assay (personal 
communication, Bio-Rad) for the method to be considered validated.  The lower and upper limits 
of quantitation (LLOQ and ULOQ, respectively) were defined as the lowest and highest spike 
concentrations tested that showed acceptable accuracy and precision.   
Analysis of cytokines in domestic cat plasma.  We quantified cytokine levels in 
domestic cat plasma collected from experimental co-infection studies with PLV and FIV 
conducted in 2005 (12) and 2010 (Sprague et al., in preparation) (Figure 1.1).  Animals were 
housed in AAALAC-International accredited facilities and all protocols were reviewed by the 
Colorado State University Institutional Animal Care and Use Committee prior to initiation.  The 
two virus strains used in these studies were PLV-1695, which is a well-characterized puma 
lentivirus isolate obtained from a British Columbia mountain lion (16), and FIV-C36 
(subsequently referred to as FIV-C), which is a highly-virulent molecular clone of domestic cat 
FIV that has also been well characterized (3).   
Samples selected from the 2005 study were 24 days post-PLV inoculation (or day -4 
relative to FIV-C inoculation) and 24 days post-FIV-C inoculation (days 24 and 52 as per (12), 
respectively).  Plasma samples from all cats in the study (n = 20) were tested at these two time-
points.  At day 24, plasma samples were collected from PLV and sham inoculated cats (n = 10 
cats per group).  At day 52, plasma samples were collected from PLV, FIV-C, co-infected (i.e., 
PLV + FIV-C; subsequently referred to as CO) and sham inoculated cats (n = 5 cats per group).  
A study with similar timelines and animal groups was conducted in 2010 (Sprague et al., 
in preparation). Plasma samples from all cats (n = 24) were tested 28 days post-PLV inoculation 
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(or day 0 relative to FIV-C inoculation) and 28-32 days post-FIV-C inoculation (referred to as 
days 28 and 56-60 days).  At day 28, plasma samples were collected from PLV and sham 
inoculated cats (n = 12 cats per group).  At days 56-60, plasma samples were collected from 
PLV, FIV-C, CO and sham inoculated cats (n = 6 cats per group).   
All plasma samples were stored in 0.5-1 ml aliquots at -80°C from the time of collection 
until cytokine quantification. The inoculation status of each cat was unknown at the time of 
testing. 
Samples with cytokine concentrations below the lowest standard tested (i.e., extrapolated 
beyond the standard curve), were assigned a value that was half the concentration of the low 
standard multiplied by five to account for the 1-in-5 sample dilution.  Median cytokine 
concentrations were compared between PLV and sham inoculated cats (days 24 and 28) using 
Mann-Whitney tests.  Among the four inoculation groups (days 52 and 56-60), median cytokine 
concentrations were compared using Kruskal-Wallis tests, and if necessary, post-hoc 
comparisons were made using Dunn’s multiple comparison tests (GraphPad Prism 5.0, La Jolla, 
CA).  p-values <0.05 were considered significant.  Statistical analysis was not performed if the 
majority of cytokine measurements fell below the established LLOQ for a given cytokine and/or 
time-point. 
Comparison of cytokine levels in plasma to cytokine mRNA expression.  We 
compared plasma cytokine levels and mRNA cytokine expression of blood cells at two time-
points for the animals in the 2005 co-infection study (n = 20).  Protein levels were detected by 
MIA and the mRNA data was previously published by TerWee et al. (2008), as fold-difference 




Microsphere immunoassay validation.  For both the inter- and intra-assay validation, 
the mean spike recoveries (accuracy) and percent CVs (precision) for each of the three analytes 
were within the acceptable ranges (Table 3.1).  The validated lower limit of quantitation (LLOQ) 
and upper limit of quantitation (ULOQ) for each analyte were 31 and 1,000 pg/ml for IFN, 63 
and 2,000 pg/ml for IL-10, and 20 and 625 pg/ml for IL-12/23.  The LLOQ of IL-12/23 
determined for plasma was lower than the value reported for the cell culture supernatant MIA 
(39 pg/ml) in Wood et al. (2011). 
 
Table 3.1.  Assay accuracy and precision over a range of analyte concentrations 
 
 
 Mean % recovery (%CV) 
Spike level IFNγ IL-10 IL-12/23 
Intra-assay    
     High 118 (12) 93 (9) 92 (9) 
     Medium 104 (11) 94 (9) 101 (6) 
     Low 83 (16) 106 (18) 106 (10) 
    
Inter-assay    
     High 103 (9) 99 (7) 101 (8) 
     Medium 107 (8) 103 (4) 105 (4) 
     Low 106 (14) 104 (13) 100 (9) 
 
 
Cytokines in domestic cat plasma.  IL-12/23 concentrations were quantifiable in all 
plasma samples tested; all concentrations were above the LLOQ (100 pg/ml adjusting for the 1-
in-5 sample dilution; Figures 3.1 and 3.2) and only two individual IL-12/23 results were above 
the validated ULOQ (3,460 pg/ml, Figure 3.1; 3,257 pg/ml Figure 3.2).  Plasma concentrations  
 40 
 
Figure 3.1.  Cytokine concentrations from domestic cat plasma samples collected 24 days post-
PLV inoculation and 24 days post-FIV-C inoculation (day 52) of the 2005 study.  The solid lines 
indicate the medians for each inoculation group.  The dashed lines indicate the concentrations of 
the lower limit of quantitation (LLOQ) and the lowest standard (LS) tested after accounting for a 
1-in-5 sample dilution (i.e., the in-well LLOQ/LS concentrations were one-fifth of those 






Figure 3.2.  Cytokine concentrations from domestic cat plasma samples collected 28 days post-
PLV inoculation and 28-32 days post-FIV-C inoculation (days 56-60) of the 2010 study.  The 
solid lines indicate the medians for each inoculation group.  The dashed lines indicate the 
concentrations of the lower limit of quantitation (LLOQ) and the lowest standard (LS) tested 
after accounting for a 1-in-5 sample dilution (i.e., the in-well LLOQ/LS concentrations were one-
fifth of those indicated in the figure). 
 
 
ranged from 337 to 3,460 pg/ml in the 2005 study, and from 479 to 3,257 pg/ml in the 2010 
study.  In both studies, the concentration of IL-12/23 was significantly higher in PLV than sham 
inoculated cats (p < 0.001).  Additionally, the concentration of IL-12/23 was significantly higher 
in FIV-C and CO inoculated cats than sham-inoculated cats (p < 0.05).  There were no 
significant differences between FIV-C or PLV groups with the CO group at day 52 (Figure 3.1) 
or days 56-60 (Figure 3.2).   
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For the majority of samples from the 2005 study, the concentrations of IFN, regardless 
of time and inoculation status, were below the lowest standard tested (Figure 3.1).  Only seven of 
the 40 samples tested had values above the LLOQ (155 pg/ml adjusting for the 1-in-5 sample 
dilution); the range of these samples was 185 to 316 pg/ml.  No values are reported for IFN 
concentrations from the 2010 study because the spikes bracketing the samples had recoveries 
lower than the acceptable range of 70-130%.  Mean recoveries for these spikes ranged from 20-
63%.  This low recovery was cytokine specific and not an overall issue with the MIA (i.e., the 
recoveries of IL-10 and IL-12/23 in the same spikes were acceptable). In subsequent 
experiments, this problem abated when freshly thawed antibodies were used instead of 
antibodies that had been stored for more than 24 h at 4°C.  However, the 2010 samples were not 
re-analyzed because of sample limitations.   
The majority of samples from the 2005 study had IL-10 concentrations above the LLOQ 
(315 pg/ml adjusting for the 1-in-5 sample dilution; Figure 3.1); the range of these samples was 
319 to 693 pg/ml.  The concentration of IL-10 was not significantly different between PLV and 
sham inoculated cats at day 24 (p = 0.79) or among the four inoculation groups at day 52 (p = 
0.68).  In the 2010 study, however, the majority of samples had concentrations of IL-10 below 
the LLOQ (Figure 3.2).  Only 2 of the 48 samples had values above the LLOQ; the 
concentrations of these samples were 438 and 600 pg/ml.   
Comparison of cytokine levels in plasma to cytokine mRNA expression.  While there 
were significant increases in IFN mRNA in the FIV-C and/or PLV infected groups at day 52 of 
the 2005 study (12), levels of IFN protein in plasma remained low (most below the LLOQ) for 
all groups (Figure 3.1).  Similarly, IL-10 mRNA expression was increased in the FIV-C infected 
group at day 52 (12), but there was no detectable difference in IL-10 protein in plasma (Figure 
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3.1).  In contrast, IL-12/23 protein levels in plasma were increased in PLV (day 24), and FIV-C 
and CO (day 52) infected groups (Figure 3.1), without any detectable change in mRNA 
expression.  Comparison of the protein:mRNA ratio for each cytokine (Figure 3.3) demonstrates 
that IL-12/23 had higher protein abundance relative to the level of mRNA expression than IL-10 
and IFN. 
DISCUSSION 
These results demonstrate the successful development and validation of a MIA for the 
quantification of domestic cat cytokines IFN, IL-10 and IL-12/23 in plasma.  To our knowledge, 
this is the first assay developed and validated for quantifying feline cytokines in plasma; the 
reagents used in the MIA are from commercially available ELISA kits validated for cell culture 
supernatants.  The advantages of developing a MIA for the detection of feline cytokines, e.g., 
compared to developing ELISAs, is that multiple analytes can be quantified simultaneously, and 
thus less time and sample volume are required to conduct comparable experiments.   
In both the 2005 and 2010 co-infection study, we detected a significant increase in 
circulating IL-12/23 during acute viral infection.  The concentration of IL-12/23 was 
significantly higher in PLV than sham inoculated cats at 24 and 28 days post-inoculation, but by 
day 52 and days 56-60 IL-12/23 concentrations were not statistically different (Figures 3.1 and 
3.2, respectively).  This transient elevation of IL-12/23 likely coincides with a decrease in viral 
load; in the 2005 study, there was a decrease in PLV proviral load in PBMCs between days 24 
and 52 (12).  Plasma concentrations of IL-12/23 were significantly higher in cats acutely infected 
with FIV-C; the concentrations of IL-12/23 were higher in FIV-C and CO inoculated cats 
compared to sham cats at 24 and 28-32 days post-inoculation (Figures 3.1 and 3.2, respectively).  




Figure 3.3.  Plasma cytokine concentrations and PBMC cytokine mRNA expression from 
domestic cat samples collected 24 days post-PLV inoculation and 24 days post-FIV-C 




viral loads.  The observed increase in IL-12 and/or IL-23 during early infection is likely 
produced by macrophages and dendritic cells for T-helper 1 (Th1) and Th17 CD4
+
 T cell 
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development, respectively (8).  The consistency of these results between two independently 
conducted studies, separated by several years, is a significant finding in an outbred species. 
In contrast to IL-12/23, the majority of IFN and IL-10 results were below the LLOQ.  It 
is possible that there are differences in these cytokines during PLV and/or FIV-C infection; 
however, at the selected time-points, these cytokines were too low to detect with the validated 
MIA.  Alternatively, the lack of detection could be because these cytokines are not elevated in 
the periphery during the acute stage of infection and/or these cytokines were affected by the 
long-term storage of the samples.   
To investigated whether the 1-in-5 plasma dilution may have contributed to the lack of 
IFN and IL-10 detection, we compared cytokine concentrations in 11 plasma samples collected 
from FIV and/or PLV infected cats diluted 1-in-2 and 1-in-5 (some samples were part of a 
different FIV-infection study).  Despite the lower dilution, IFN and IL-10 were quantifiable in 
only a few more samples (three additional samples were quantifiable for both IFN and IL-10).  
Additionally, to investigate whether IFN and IL-10 were elevated at earlier time-points, we 
tested plasma samples collected a) 3 days post-PLV and 3 days post-FIV-C from the 2005 co-
infection study using a 1-in-5 dilution, and b) 14 days post-PLV and 14 days post-FIV-C from 
the 2010 co-infection study using a 1-in-2 dilution.  At 3 days post-infection, only 2 of the 40 
samples had values above the LLOQ for both IFN and IL-10 (i.e., two separate cats per 
analyte).  At 14 days post-infection, the majority of samples (35 of 48) had values below the 
LLOQ for both IFN and IL-10.  No definitive conclusions could be made from these 
experiments because the samples tested were from two different time points and studies, and 
were tested at different dilutions.  No additional sample dilution experiments were conducted, 
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but these results showed that IFN and IL-10 were only detected at very low concentrations in 
the majority of the samples tested.   
The lack of agreement between the plasma cytokine data reported here and the mRNA 
data reported in TerWee et al. (2008) supports the premise that mRNA expression does not 
necessarily predict protein abundance.  Comparison of circulating protein levels relative to 
mRNA transcript demonstrates that IL-10 and IFN tend to have a significantly lower 
protein:mRNA ratio than IL-12/23.  The observed differences could be attributed to various 
factors associated with post-transcriptional regulation or protein detection (6), and/or the effect 
of long-term storage of samples.   
In summary, the MIA described here could be used to evaluate domestic cat cytokine 
responses elicited by a variety of diseases.  Additionally, the assay could be expanded to include 
other cytokines for which reagents are commercially available, including IL-1, IL-2, IL-4, IL-6 
and/or tumor necrosis factor .   
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CHAPTER 4:  MICROSPHERE IMMUNOASSAYS FOR THE QUANTIFICATION OF 
DOMESTIC CAT ANTIBODIES AND THE DETECTION OF ANTIBODIES AGAINST 





Microsphere immunoassay (MIA) technology allows for the simultaneous detection of 
multiple analytes (e.g., cytokines, chemokines or antibodies; reviewed in (62)) within biological 
samples.  Multiple sets of microspheres, each with a unique ratio of internal dyes and conjugated 
with a different capture reagent (e.g., antibodies or antigen), are combined and incubated with an 
aliquot of sample.  The detection or quantification of each analyte is based on the fluorescence 
intensity of the detection antibody reporter dye.  The advantages of MIAs, compared to 
traditional immunoassays (e.g., enzyme-linked immunosorbent assays (ELISAs)), are that less 
time and sample volume are required.  MIAs have been developed for the detection of antibodies 
to various animal and human pathogens, including avian influenza (63), foot-and-mouth disease 
virus (14), human immunodeficiency virus (HIV; (4, 59)), Plasmodium falciparum (27), 
Toxoplasma gondii (38), West Nile virus (66), and a panel of five select agents (Bacillus 
anthracis, Yersinia pestis, Francisella tularensis, ricin toxin and staphylococcal enterotoxin B; 
(6)).  Assays, such as these, can be used for screening or diagnostic purposes (6), or investigating 
antibody kinetics (63). 
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of the domestic 
cat (Felis catus) that is similar to HIV in terms of viral structure, transmission, target cells and 
disease progression, including the hallmark decline of peripheral CD4
+
 T-cells (25, 44, 69).  
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Despite a vigorous immune response, FIV and HIV infections are life-long and infected 
individuals succumb to opportunist infections.  Given the high degree of similarity between these 
two viruses, the domestic cat is an appropriate animal model for evaluating the immune response 
associated with lentiviral infections. 
Domestic cats develop antibodies to various FIV proteins, including core proteins, such 
as capsid (CA) and matrix, as well as the two membrane proteins, surface (SU) and 
transmembrane (TM) (24, 29, 34, 42).  Antibodies to these viral proteins are generally first 
detected within weeks post-infection (9, 10, 24, 29, 31, 46, 47) and increase during the early 
stage of infection (10, 31, 46, 47).  The level and kinetics of the antibody response varies 
depending on viral strain and/or inoculation route, as well as among individual cats (9, 10, 31, 
47).  Although the majority of these studies have focused on the IgG FIV-specific antibody 
response, IgM and IgA FIV-specific antibodies are also detected in plasma/sera (9, 29).  In 
addition, FIV-infected domestic cats exhibit elevated levels of gamma-globulins (28, 68), as a 
result of elevated levels of IgG antibodies (1, 29).  The elevated IgG levels are attributed to 
polyclonal B-cell activation, rather than entirely virus-specific, as antibodies generated after FIV 
infection are specific for a variety of non-viral and self antigens (26).  Although the cause of the 
polyclonal activation with FIV is unknown, with HIV the SU protein (gp120) is able to induce a 
CD4
+
 T-cell independent B-cell response (32); gp120 can activate a subset of B-cells and trigger 
antibody class-switching through an innate pathway involving the mannose C-type lectin 
receptor and B cell-activating factor of the tumor necrosis factor family (BAFF) (32).  Polyclonal 
B-cell activation is not unique to lentiviruses; many viruses, bacteria and parasites can trigger a 
polyclonal B-cell response (reviewed in (41)).  Despite the number of studies that have evaluated 
the antibody response of FIV-infected domestic cats (1, 9, 10, 24, 26, 29, 31, 34, 42, 46, 47), 
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there are limited data on the development of total IgG and IgA, and IgG and IgA FIV-specific 
antibodies during the early stage of infection. 
Here we describe the development and validation of domestic cat-specific MIAs for a) 
the quantification of total IgG and IgA levels in plasma, and b) the detection IgG and IgA 
antibodies to feline CD134 (the primary cell receptor for FIV (16, 49)), and FIV CA and SU 
proteins in plasma (assays subsequently referred to as recombinant protein (rProtein)).  The 
rProteins included in the MIAs were selected because previous FIV studies have documented an 
antibody response to these proteins (9, 10, 24, 29, 31, 34, 42, 46, 47).  Domestic cats develop a 
robust α-CA antibody response (e.g., detectable at 1:3,200 sample dilution (9, 23)) within weeks 
post-infection (9, 42).  Although α-CA antibodies are non-neutralizing, these antibodies may 
play a role in disease progression.  For example, the presence of α-Gag/CA antibodies correlates 
with delayed HIV disease progression (7, 12, 13, 40, 64).  Antibodies to SU protein are 
detectable within weeks post-infection (31), and antibodies to specific SU epitopes are capable of 
neutralizing the virus (e.g., V4 and V5 regions (48, 50, 51, 65)).  Although neutralizing 
antibodies develop slowly over time (e.g., years post-FIV infection (35)), passive immunization 
experiments with plasma from cats 3 weeks post-infection (8) or sera from cats 9-10 months 
post-infection (33) were able to prevent FIV infection.  Domestic cats develop α-CD134 
antibodies that bind to a cryptic epitope on the CD134 receptor, which is only exposed once the 
virus SU protein is bound (18), and this binding results in the displacement of SU from the cell 
receptor (31).  In a recent study, it was noted that FIV-infected cats that developed 
autoantibodies to CD134 tended to have lower viral loads and less virulent disease than cats that 
did not develop anti-receptor antibodies (31).   
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The utility of the four MIAs described here were demonstrated by testing plasma samples 
collected from domestic cats experimentally infected with various FIV strains.  Plasma samples 
selected for testing were from a) a study evaluating impacts of co-infection with pathogenic and 
apathogenic FIVs (55); and, b) a study evaluating parental and chimeric FIVs of varying 
pathogenicity (57).  These two studies were selected because significant information about 
immunopathology and viral load has already been determined.  The goal of this study was to 
determine whether the kinetics and/or level of the antibody response is related to virus 
strain/clinical outcome, and to estimate the percent of IgG antibodies that are CA- or SU-
specific.   
Briefly, in the co-infection study, domestic cats were inoculated intravenously (IV) with 
PLV-1695 (subsequently referred to as PLV) and/or FIV-C36 (clade C virus; subsequently 
referred to as FIV-C) (55).  PLV is a well-characterized puma lentivirus isolate obtained from a 
British Columbia mountain lion (60), and FIV-C is a highly-virulent molecular clone of domestic 
cat FIV that has been well characterized (19).  In this study, peripheral CD4
+ 
T-cells in FIV-C 
cats decreased after inoculation and remained low compared to their baseline values for the 
duration of the study.  In contrast, peripheral CD4
+ 
T-cells in co-infected (CO) cats (i.e., 
inoculated with PLV 28 days before FIV-C inoculation) decreased 9 days after FIV-C 
inoculation and then rebounded to levels similar to their baseline for the duration of the study.  
Of note, there was no difference in the plasma viral loads between FIV-C and CO cats at the 
time-points tested.  Although data from this study suggested that the non-adaptive immune 
response contributed to the observed CD4
+
 T-cell maintenance, the antibody response was only 
examined at a single time-point.  At 31 days post-FIV-C inoculation, there was no difference in 
serum neutralizing antibody titers among the groups (55). 
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In the FIV-chimera study, domestic cats were inoculated IV with in vivo passaged FIV-C, 
FIV-PPR (clade A virus; subsequently referred to as FIV-A) or a chimera virus FIV-PCenv 
(subsequently referred as FIV-A/C) (57).  The FIV-A/C virus has the FIV-A backbone with FIV-
C accessory and envelope genes (i.e., FIV-C vif, orfA, env and part of the rev response element 
or 3’ elements) (20).  The parental viruses, FIV-C and FIV-A, differ in terms of virulence and 
tropism.  FIV-A is neurotropic (22) and causes less severe disease in the periphery than FIV-C 
(e.g., lower viral loads, and less severe decreases in CD4
+
 T-cells and neutrophils (43)).  The 
purpose for constructing the chimera virus and testing in vivo was to determine whether the 
envelope region contributed to the increased pathogenicity of the FIV-C virus (21, 43).  The 
results of the virus-passaged in vivo study indicated that, in general, the FIV-C cats had the 
highest viral and proviral loads, followed by the FIV-A/C and then FIV-A infected cats (57), 
suggesting that pathogenicity is linked to the 3’ viral elements.  To date, the antibody response 
has not been evaluated for any of the chimera in vivo studies (20, 57).   
MATERIALS AND METHODS 
Antibodies, standards and microspheres.  Reagents and microspheres used for the 
development of the four MIAs are summarized in Table 4.1.  MagPlex-C microspheres were 
obtained from Bio-Rad (Hercules, CA).  Cat reference serum was used for total IgG and IgA 
standard curves; undiluted reference serum contains 5.4 mg/ml of IgG and 0.22 mg/ml of IgA 
(Bethyl Laboratories, Montgomery, TX).  The concentration of albumin in the reference serum is 
not reported; the detection of albumin served as a control to confirm that the standard or sample 
was loaded into each well.  Anti-cat IgG, IgA and albumin antibodies (Bethyl Laboratories) were 
coupled to the microspheres as capture reagents, as well as conjugated with phycoerythrin (PE; 
EasyLink R-Phycoerythrin conjugation kits, Abcam, Cambridge, MA) to use as detection  
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Table 4.1.  Components used for the development of the four domestic cat MIAs. 
 
Assay Total IgG rProtein IgG Total IgA rProtein IgA 
     
Analytes detected IgG α-CA IgG IgA α-CA IgA 
 Albumin α-SUFIV-A IgG Albumin α-SUFIV-A IgA 
  α-SUFIV-C IgG  α-SUFIV-C IgA 
  α-CD134 IgG  α-CD134 IgA 
  α-Fc IgG  α-Fc IgA 
  α-FeLV IgG  α-FeLV IgA 
  Albumin  Albumin 
     
Microspheres     
Microspheres/analyte per well 2,500 2,500 2,500 2,500 
Capture reagent (region)
a
 α-cat IgG Ab
b 
(77) CA (35) α-cat IgA Ab
b
 (63) CA (35) 
 α-cat albumin Ab
b
 (13) SUFIV-A (65) α-cat albumin Ab
b
 (13) SUFIV-A (65) 
  SUFIV-C (43)  SUFIV-C (43) 
  CD134 (54)  CD134 (54) 
  Fc (29)  Fc (29) 
  FeLV (28)  FeLV (28) 
  α-cat albumin Ab
b
 (13)  α-cat albumin Ab
b
 (13) 
     
Standards and plasma samples     
Standard
b
 range (ng/ml) 7.8-1,000 - 3.9-500 - 
Plasma dilution 1:200,000 1:50 1:10,000 1:50 
Volume per well (μl) 50 50 50 50 
Incubation (min) 60 60 60 60 
     
Primary Ab     
Antibody (ng/ml) - α-cat IgG mAb
d
 (400) - - 
Volume per well (μl) - 50 - - 
Incubation (min) - 30 - - 
     
Detection Ab     
Antibodies (ng/ml) PE α-cat IgG
c
 (400) PE α-mouse IgG
e
 (400) PE α-cat IgA
c
 (400) PE α-cat IgA
c
 (400) 
 PE α-cat albumin
c
 (200) PE α-cat albumin
c
 (200) PE α-cat albumin
c
 (200) PE α-cat albumin
c
 (200) 
Volume per well (μl) 100 50 100 50 
Incubation (min) 30 30 30 30 




MagPlex-C microsphere region was assigned by the manufacturer; the region is based on the ratio of two internal dyes  
b
 Reagents from Bethyl Laboratories 
c 
Unconjugated antibodies (Bethyl Laboratories) were conjugated with phycoerythrin (PE) using the EasyLink  
R-Phycoerythrin conjugation kits (Abcam) 
d 
Monoclonal antibody (GPB2-2B1) from Custom Monoclonals International 
e 
Antibody from R&D Systems  
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antibodies.  A primary antibody was used for the detection of α-rProtein IgG antibodies because 
the α-IgG detection antibody cross-reacts with the Fc-tag on the recombinant proteins; the 
primary antibody was a cat-specific α-IgG monoclonal antibody (Custom Monoclonals 
International, Sacramento, CA).  The microsphere with Fc (Sino Biological Inc., Beijing, China) 
attached served as a control for the Fc-tag on the recombinant proteins, and the microsphere with 
feline leukemia virus (FeLV; FL74 provided by J. Elder) attached served as a non-FIV viral 
control.   
Recombinant FIV-C CA protein.  The sequence encoding the CA protein (1,038 to 
1,703; 666 nucleotides) was amplified from a molecular clone of FIV-C (19) using standard PCR 
protocols.  The primers, which included restriction sites (underlined) for directional insertion into 
the plasmid, as well as start (italicized) and stop codons (wave underlined), were as follows:  
Fwd (BamHI) 5’-CGCGGATCCATGCCTATCCAAATAGTAAATGGAGCAC-3’ and Rev 
(EcoRI) 5’-CCGGAATTCCTACTATAATTGCATTTTGTATGCCGGTG-3’.  The pGEX-2T 
plasmid (GE Healthcare Life Sciences, Piscataway, NJ; provided by J. Rovnak) used for protein 
expression includes a glutathione S-transferase (GST) gene upstream of the insertion site, a 
thrombin cleavage site between the GST and insertion site, and a gene for ampicillin resistance.  
Purified plasmid and PCR product were digested with BamHI and EcoRI restriction enzymes, 
and ligated with T4 DNA ligase according to manufacturer recommendations (New England 
BioLabs, Ipswich, MA).  The plasmid was propagated in One Shot
®
 TOP10 Chemically 
Competent E. coli (Life Technologies, Grand Island, NY).  Purified plasmid was sequenced 
(Proteomic and Metabolomics Facility, Colorado State University) to confirm capsid insertion 
using the following primers:  Fwd 5’-GGGCTGGCAAGCCACGTTTGGTG-3’ and Rev 5’-
CCGGGAGCTGCATGTGTCAGAGG-3’. 
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Chemically competent BL21 E. coli (provided by J. Rovnak) were used for protein 
expression.  The transformed E. coli were grown in 1 L of broth (LB broth + 50 μg/ml 
ampicillin; 140 rpm at 37°C); the cells were induced with 0.5 mM isopropyl-β-D-
thiogalactopyranoside when the OD600 reached 0.6 and incubated for an additional two hours.  
Pelleted bacteria (10,000 x g for 10 min at 4°C) were lysed with BugBuster
®
 Protein Extraction 
Reagent according to manufacturer recommendations (EMD Chemicals, Inc., San Diego, CA).  
The GST-tag was removed from the CA protein using thrombin.  GST and thrombin were 
removed from solution using glutathione sepharose 4B beads and benzamidine sepharose 4 fast 
flow beads, respectively, according to manufacturer recommendations (GE Healthcare Life 
Sciences).  The presence of purified CA protein was confirmed by SDS-PAGE and by 
immunoblot analysis (band ~26 kDa).  The protein storage buffer was exchanged to PBS by 
dialysis, and the protein concentration was determined using a BCA protein assay kit (Thermo 
Scientific, Waltham, MA) before storage at -80°C. 
Recombinant surface proteins and CD134.  Recombinant SUC36-Fc, SUPPR-Fc and 
CD134-Fc (subsequently referred to as SUFIV-C, SUFIV-A and CD134; provided by J. Elder) were 
expressed and purified from CHO cells, as previously described (15, 17).  The Fc tag is the Fc 
domain of human IgG1(15, 17); for SUFIV-C the Fc tag is N-terminus, whereas for SUFIV-A and 
CD134 the Fc tag is C-terminus.  [Note: Experiments were conducted to express FIV-C SU and 
TM proteins in both baculovirus-insect cell and E. coli expression systems.  However, as the 
initial expression experiments were unsuccessful and time was limited, the rProteins provided by 
J. Elder were used in these assays.  See appendix for details.] 
 Coupling of capture reagents to microspheres.  Magnetic microspheres were 
conjugated with capture antibodies, recombinant proteins or whole virus (Table 4.1) as 
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previously described (67), with the exception that microsphere concentrations were determined 
using a hemocytometer.  To confirm protein coupling, microspheres (5,000 per well) were 
incubated with primary antibodies and/or PE-conjugated detection antibodies as follows: PE α-
goat antibody (R&D Systems, Minneapolis, MN) for IgG, IgA and albumin microspheres; FIV
+
 
plasma and PE α-cat IgG antibody for CA microspheres; pooled α-FIV SU monoclonal 
antibodies (Custom Monoclonals International) and PE α-mouse IgG antibody (R&D Systems) 
for SUFIV-A and SUFIV-C microspheres; α-human IgG Fc (Sino Biological Inc.) and PE α-mouse 
IgG antibody for CD134 and Fc microspheres; and A2 mouse ascites (provided by C. Mathiason) 
and PE α-mouse IgG antibody for FeLV microspheres.  A median fluorescence intensity (MFI) 
of >2,000 indicated successful coupling (Bio-Rad).   
Assay development for total IgG and IgA.  Assay development and optimization for 
the total IgG and IgA MIAs were conducted in the following order: (i) optimization of capture 
antibody concentration, (ii) optimization of detection antibody concentration, (iii) determination 
of standard range and sample dilution, and (iv) comparison of IgG and IgA standard curve MFI 
alone or multiplexed with albumin.  Capture antibody concentrations tested were 1, 2.5, 5, 7.5, 
10 and 15 μg per 10
6
 microspheres.  Detection antibody concentrations tested were 200, 400, 600 
and 833 ng/ml.  The standard curve range and sample dilution were optimized simultaneously; 
plasma samples from FIV-infected and uninfected domestic cats were tested at different dilutions 
with various standard curve ranges to ensure that at a specific dilution the majority of sample 
concentrations were within the standard range.  Sample dilution and standard ranges tested were 
initially based on those reported for quantitative ELISAs (11).  To determine whether the MFI of 
IgG or IgA standard curves were affected by multiplexing with albumin, single and multiplex 
 59 
standard curves were compared.  In each of these experiments, approximately 2,500 
microspheres per analyte were added to each well. 
Total IgG and IgA MIA protocols.  The protocols used for total IgG and IgA MIAs 
were similar to the method described previously (67), with the following modifications: 
standards, samples and spikes were diluted in assay buffer (PBS, 1% BSA, pH 7.4; Sigma-
Aldrich, St. Louis, MO); diluent controls (blanks) consisted of assay buffer; diluent controls, 
samples and standards were incubated for 60 min; detection antibody volumes were 100 μl; and 
after the final wash microspheres were re-suspended in 100 μl of 0.5% formaldehyde (37%, w/w; 
Fisher Scientific, Pittsburgh, PA) in assay buffer.  The modifications to incubation time and 
volume were based on a protocol for a washed serological assay using magnetic microspheres 
(Luminex Corporation, Austin, TX).  Each experiment included an eight-point standard curve  
(2-fold dilution series) and four diluent control wells.  All samples and standards were run in 
duplicate.  Reagent concentrations, volumes and incubation times are summarized in Table 4.1.  
Bio-Plex
™
 200 (Bio-Rad) maintenance and data analysis (Bio-Plex
™
 Manager 5.0, Bio-Rad) 
were identical to the methods previously described (67).  MFI was calculated from ≥100 
microspheres per analyte per well.  The standard curves were used to calculate antibody 
concentrations in plasma samples.  Acceptable standard recovery was 70–130% of the nominal 
value (Bio-Rad).  
Validation total IgG and IgA protocols.  Intra- and inter-assay experiments were 
conducted to determine both the accuracy and precision of the total IgG and total IgA MIAs.  
These experiments were similar to the method previously described (67).  Briefly, spiked 
samples (samples of known concentration) were prepared similar to the standards, and were run 
in five separate inter-assay experiments (2 wells at each spike concentration) and one intra-assay 
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experiment (10 wells at each spike concentration).  Spike concentrations were 16, 125 and 500 
ng/ml for IgG, and 8, 63 and 250 ng/ml for IgA.  Acceptable accuracy (spike recovery) was 70-
130% of the nominal value (Panomics, Santa Clara, CA), and acceptable precision (coefficient of 
variation (CV)) for the mean spike recovery at each concentration was required to be <20% for 
the intra-assay and <30% for the inter-assay (personal communication, Bio-Rad) for the method 
to be considered validated.  
Assay development for rProtein MIAs.  Assay development and optimization for the 
rProtein MIAs were conducted in the following order: (i) optimization of capture reagent 
concentration, (ii) comparison of FIV and naïve plasma sample MFI between single and 
multiplexed microspheres, (iii) establishment of FIV-C and naïve plasma pools, and (iv) 
determination of sample dilution.  Concentrations of capture reagent tested were 0.5, 1, 2.5, 5, 
7.5 and 10 μg per 10
6
 microspheres for all analytes except the two SU proteins.  Because stocks 
of the SU proteins were limited, the optimal concentration found for the other analytes was used 
for SU coupling (i.e., 5 μg per 10
6
 microspheres).  The detection antibody concentrations used 
were the optimal concentrations of the total IgG and IgA MIAs.  To determine whether analyte 
MFIs were affected by multiplexing, FIV-C and naïve plasma samples were tested with single 
and multiplexed microspheres.  Since standards are not available for the analytes in the rProtein 
MIAs, FIV-C and naïve plasma pools were established and used in each experiment as assay 
controls.  Plasma samples from four FIV-C cats and four naïve cats were tested individually with 
both the IgG and IgA rProtein MIAs.  Samples with high MFI for CA, SUFIV-A, SUFIV-C and 
CD134 were included in the positive pool, and samples with low MFI for CA, SUFIV-A, SUFIV-A, 
CD134, Fc and FeLV were included in the naïve pool.  None of the FIV-C plasma samples had 
high MFI values for IgA antibodies against CD134.  Separate reference pools were established 
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for the IgG and IgA assays.  Plasma samples used during steps (i) to (iii) were diluted 1:50 in 
assay buffer; this dilution was chosen as it is a dilution used to detect FIV antibodies by 
immunoblot assay (5).  Samples dilutions tested were 1:25, 1:50, 1:100, 1:500 and 1:1,000 for 
detecting α-rProtein IgG antibodies, and 1:5, 1:10, 1:25 and 1:50 for detecting α-rProtein IgA 
antibodies.  Because there was not an ideal dilution for all analytes (i.e., at low dilutions some 
analytes were maximized, whereas at high dilutions some analytes were undetectable), we 
standardized the assay by using a 1:50 dilution for both the IgG and IgA rProtein MIAs.  In each 
of these experiments, approximately 2,500 microspheres per analyte were added to each well. 
rProtein IgG and IgA MIA protocols.  The protocols used for the rProtein MIAs were 
similar to the method described previously (67), with the following modifications: samples were 
diluted in assay buffer; diluent controls (blanks) consisted of assay buffer; diluent controls and 
samples were incubated for 60 min; and after the final wash, microspheres were re-suspended in 
100 μl of 0.5% formaldehyde in assay buffer.  Each experiment included FIV-C and naïve 
reference samples, and four diluent control wells.  All samples and reference pools were run in 
duplicate.  Reagent concentrations, volumes and incubation times are summarized in Table 4.1.  
Bio-Plex
™
 200 maintenance was identical to the method previously described (67).  The median 
fluorescence intensity (MFI) was calculated from ≥100 microspheres per analyte per well (Bio-
Plex
™
 Manager 5.0), and the MFI per sample was used for data analysis.   
Validation rProtein IgG and IgA protocols.  Intra- and inter-assay experiments were 
conducted to determine the precision of the rProtein MIAs for CA, SUFIV-A, SUFIV-C and CD134.  
These experiments were similar to the method previously described (67), except that FIV-C and 
naïve reference pools were used in place of standards.  Reference samples were diluted 1:50 with 
assay buffer, and were run in five separate inter-assay experiments (2 wells per sample) and one 
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intra-assay experiment (10 wells per sample).  Two separate FIV-C reference pools (early and 
late stage of infection) were used to validate the IgG assay because at early time-points α-CD134 
IgG antibodies are not detectable and at later time-points the MFI for CA and SUFIV-C were 
maximized.  Acceptable precision (%CV) for the mean MFI of each reference was <20% for the 
intra-assay and <30% for the inter-assay (personal communication, Bio-Rad).  The rProtein 
assays were not validated for Fc and FeLV, as these microspheres served as controls. 
Co-infection study.  Antibody levels were measured in domestic cat plasma collected 
from an experimental co-infection study with PLV and FIV-C (55) (Figure 1.1).  Animals (n = 
20; 5 cats per group) were housed in AAALAC-International accredited facilities, and all 
protocols were reviewed by the Colorado State University Institutional Animal Care and Use 
Committee prior to initiation.  EDTA plasma samples were collected in 0.5-1 ml aliquots and 
stored at -80°C.  Data for one sham cat is not included in the results presented here because of an 
underlying condition that affected the antibody response. 
Plasma samples from -4, 9, 17, 24 and 66 days post-FIV-C inoculation were tested with 
each of the four antibody MIAs (24, 37, 45, 52 and 94 days post-PLV inoculation, as referred to 
in TerWee et al. 2008).  These time-points were selected to a) determine whether antibodies to 
PLV cross-react with FIV-C viral proteins (i.e., antibodies at day -4), and b) determine whether 
CO cats developed a higher antibody response than FIV-C cats over time.  Plasma samples for 
each cat were available for testing at nearly all of the time-points selected (89 of 95 samples).  
The SUFIV-A microsphere was not included in the rProtein assays because only the FIV-C virus 
was used in this study.  The inoculation status of each cat was unknown at the time of testing. 
Chimera study.  Antibody levels were measured in domestic cat plasma collected from 
an experimental infection study involving parental FIVs of high (FIV-C) or low (FIV-A) 
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pathogenicity, as well as a chimera (FIV-A/C) with intermediate pathogenicity (57).  Housing 
and approval for animals (n = 20; 5 cats per group) were similar to those for the co-infection 
study.  EDTA plasma samples were collected in 0.5-1 ml aliquots and stored at -80°C.  Two cats 
(one FIV-C and one FIV-A) diagnosed with allergic dermatitis unrelated to the study protocol 
were euthanized before the conclusion of the study (57), and are not included in the data 
presented here.   
Plasma samples from days 7, 14, 21, 28, 35, 67 and 326 post-FIV inoculation were tested 
in each of the four antibody MIAs.  These time-points were selected to a) determine whether the 
antibody levels differed among the virus-infected cats over time, and b) determine whether 
antibody levels correlated with virus strains/clinical outcome.  All plasma samples (n = 18) were 
available for testing from each of the selected time-points.  The inoculation status of each cat 
was unknown at the time of testing. 
In preliminary experiments, it was noted that antibodies generated against one virus 
bound to the SU protein of the other virus (e.g., antibodies of a FIV-C infected cat bound to 
SUFIV-A).  Nonetheless, the presence of these cross-reactive antibodies did not drastically affect 
the MFI of antibodies bound to the matching SU protein (e.g., antibodies of a FIV-C infected cat 
bound to SUFIV-C).  Thus, both microspheres were included in the assays; however, only the virus 
matched SU protein data are reported (i.e., SUFIV-C data for FIV-C and FIV-A/C cats, and  
SUFIV-A data for FIV-A cats).  The values reported for the sham cats are the average MFI of 
SUFIV-A and SUFIV-C. 
Estimating percent FIV-specific IgG antibodies.  To estimate the proportion of the 
total IgG response that was FIV-specific, the MFI for total IgG (1:200,000 dilution) was 
compared to the MFIs for CA and SU of the same sample serially diluted (1:50 to 
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1:10,000/1:20,000).  The dilution at which the CA or SU MFI was closest to the total IgG MFI 
was used for the percent estimation (e.g., 1:200,000 divided by 1:5,000 equals 0.025 or 2.5%).  
These CA and SU percentages were then expressed as a percentage of the increase in the total 
IgG response for each cat (i.e., relative to the average IgG response of the sham cats at the same 
time-point).  Thus, the estimates reported are the percentages of CA- or SU-specific IgG 
antibodies relative to the increase in IgG antibodies due to infection.  These experiments and 
calculations were conducted for FIV-C and CO cats on day 66 of the co-infection study, and for 
FIV-C, FIV-A/C and FIV-A cats on day 326 of the chimera study.  
Statistical analyses.  Repeated-measures ANOVAs were used to examine antibody 
responses over time among the treatment groups in the co-infection and chimera studies.  Of 
particular interest were the time-by-treatment effects, as these indicate differences in antibody 
kinetics (the difference in responses among the groups over time).  Prior to analysis, these data 
were examined and normalized by log10-transformation.  When significant time-by-treatment 
effects were noted, pairwise repeated-measures ANOVAs were conducted to determine which 
treatments differed from one another over time.  Differences in the average level of the antibody 
response (average across all time-points) were also noted between pairs.  One-way ANOVAs and 
pairwise comparisons were used to examine the antibody response among the treatment groups 
at a select set of single time-points, such as when the antibody levels were only elevated at 
particular time-point(s).  Analyses were conducted in R (http://www.r-project.org/), and p-values 
<0.05 were considered significant.   
RESULTS 
Microsphere assay conditions.  Optimized assay conditions are summarized in Table 
4.1.  The optimal concentration for capture reagents was 5 μg per 10
6
 microspheres.  Each 
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analyte had only minor differences between single and multiplex standard curve MFI or between 
single and multiplex reference sample MFI, indicating that the analytes could be evaluated in the 
multiplexed format.   
Microsphere immunoassay validations.  The intra- and inter-assay mean spike 
recoveries (accuracy) and percent CVs (precision) were within the acceptable ranges for both the 
total IgG and total IgA MIAs (Table 4.2).  For the rProtein MIAs, the intra- and inter-assay 
percent CVs were within the acceptable range for CA, SUFIV-A, SUFIV-C and CD134 (Table 4.3).  
The values for IgG antibodies to Fc and FeLV in the two FIV reference pools ranged from 17-53 
MFI and 7-49 MFI, respectively.  The values for IgA antibodies to Fc and FeLV in the FIV 
reference pool were 23-52 MFI and 11-37 MFI, respectively.  For the naïve reference pools, the 
values for IgG and IgA rProtein antibodies to all of the analytes combined ranged from 4-46 MFI 
and 2-68 MFI, respectively.   
Co-infection study antibody response.  Total IgG.  The kinetics and level of the total 
IgG response differed among the four treatment groups (p-values <0.001; Figure 4.1a).  There 
were significant differences in the antibody kinetics between all pairs (p-values <0.05), except 
for FIV-C and CO, and sham and PLV cats.  Total IgG was on average higher for CO than FIV-
cats, and higher for PLV than sham (p-values <0.001).  The average level of the PLV total IgG 
response was similar to FIV-C cats, but significantly lower than the CO cats (p <0.0001).  The 
decrease in total IgG for the PLV cats at day 17 is likely because three of the five plasma 
samples were not available for testing; the two cats with samples available on day 17 had the 
lowest total IgG values at the other time-points tested.  The concentrations for total IgG ranged 
from 7.0 to 45.4 mg/ml. 
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Table 4.2.  Total IgG and IgA assay accuracy and precision over a range of analyte 
concentrations.  Acceptable spike recovery was 70-130% of the nominal value.  The coefficient 
of variation (CV) for the mean spike recovery was required to be <20% for the intra-assay and 
<30% for the inter-assay. 
 
 




  High 89 (15) 101 (12) 
Medium 93 (7) 102 (5) 
Low 87 (3) 105 (5) 
   Inter-assay 
  High 88 (12) 82 (5) 
Medium 93 (6) 96 (5) 






Table 4.3.  IgG and IgA rProtein mean MFI and precision for the FIV-C reference samples.  The 
coefficient of variation (CV) for the mean MFI was required to be <20% for the intra-assay and  
<30% for the inter-assay.  The values reported for IgG antibodies to CA and SUFIV-C are from a 
different FIV-C plasma pool than values reported for IgG antibodies to SUFIV-A and CD134.  
Plasma samples used for the reference samples were from the early (22 and 29 days post-
infection) and late (298, 325 and 346 days post-infection) stage of infection.  IgA antibodies to 





Mean MFI (%CV) 
 
sample CA SUFIV-A SUFIV-C CD134 
IgG antibodies 
    
Stage of infection Early Late Early Late 
Intra-assay 14,085 (2) 14,883 (2) 4,741 (1) 5,715 (1) 
Inter-assay 13,699 (8) 13,883 (11) 4,585 (8) 5,422 (13) 
 
    
IgA antibodies 
    
Stage of infection Late Late Late Late 
Intra-assay 626 (5) 2,285 (5) 4,880 (2) - 
Inter-assay 694 (10) 2,455 (6) 5,380 (4) - 
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a)            b) 
                                       
c)     d) 
                                                    
                              
Figure 4.1.  Total IgG (a), α-CA IgG (b), α-SUFIV-C IgG (c) and α-CD134 IgG (d) responses for cats from the co-infection study.  Cats 
were inoculated on day -24 with PLV (PLV and CO groups) and/or on day 0 with FIV-C (FIV-C and CO groups).  Data points 
represent the mean MFI + SE.  The dotted horizontal lines represent the level of non-specific antibody binding or the mean MFI + 
2SD for α-Fc IgG antibodies (MFI 140).  Arrows indicate where the MFI for individual cats/group means were maximized with 
current assay conditions (i.e., using a 1:50 sample dilution).   
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Anti-capsid IgG.  The α-CA IgG MFI for individual cats/group means were maximized 
from day 17 through 66 with the current assay conditions (i.e., 1:50 dilution; Figure 4.1b).  Days 
24 and 66 were excluded from the statistical analyses because the mean MFIs reported for CO 
and FIV-C cats were maximized (i.e., any differences in the antibody response that might have 
occurred at these time-points were not detected).  For day -4 through 17, the antibody response 
differed over time among the four treatment groups (p <0.001).  There were significant 
differences in the antibody kinetics of FIV-C cats with both sham and PLV cats, and CO cats 
with both sham and PLV cats (p-values <0.05), but there were no differences between FIV-C and 
CO or sham and PLV cats.  The α-CA IgG response was on average higher for CO than FIV-C 
cats, and higher for PLV than sham cats (p-values <0.001).  Antibodies generated during PLV 
infection cross-react with FIV-C CA protein, as indicated by the elevated α-CA IgG levels at day 
-4 (i.e., four days before FIV inoculation) in the two groups of cats inoculated with PLV (PLV 
and CO).  
Anti-surface IgG.  The α-SUFIV-C IgG response differed over time among the four 
treatment groups (p <0.001; Figure 4.1c).  There were significant differences in both the kinetics 
and level of the antibody response of FIV-C cats with both sham and PLV cats, and CO cats with 
both sham and PLV cats (p-values <0.001), but there were no differences between FIV-C and 
CO or sham and PLV cats.   
Anti-CD134 IgG.  The α-CD134 IgG data were not analyzed by repeated-measures 
ANOVA because the majority of the values were below the non-specific antibody binding level 
(MFI of 140; Figure 4.1d).  None of the cats had IgG antibodies attributed to CD134 on day -4, 
and none of the sham or PLV cats had antibodies attributed to CD134 at any of the time-points 
tested.  At 9, 17 and 24 days post-infection, only one cat in the CO group clearly had elevated α-
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CD134 IgG antibodies (MFI 732, 529 and 253, respectively); however, by day 66 this cat no 
longer had detectable antibodies.  (Note: On day 9, two cats in the CO had MFI values of 142 
and 155, which were only slightly above the non-specific antibody binding level).  On day 66, 
three of the five cats in the CO group had detectable antibodies (MFI range 213 to 3,422), and all 
five of the cats in the FIV-C group had detectable antibodies (MFI range 327 to 7,452).  
Although there was a statistical difference among the groups at day 66 (p <0.001), there was no 
difference between the two groups that had an IgG antibody response attributed to CD134 (i.e., 
FIV-C and CO cats).   
Total IgA.  There were no significant differences among the treatment groups over time 
for total IgA (range 0.2 to 7.5 mg/ml, average 1.4 mg/ml; Figure 4.2a). 
Anti-capsid IgA.  There were no significant differences among the treatment groups over 
time for α-CA IgA (MFI range 36 to 7,807; average MFI of 370; Figure 4.2b).   
Anti-surface IgA.  Because the majority of α-SUFIV-C IgA values (87 of 89) were below 
the non-specific antibody binding level (MFI of 588), the IgA response observed could not be 
distinguished between the recombinant protein and the Fc tag (Figure 4.2c).   
Anti-CD134 IgA.  None of the cats had detectable IgA antibodies to CD134; all values 
were below the non-specific antibody binding level (MFI 588; Figure 4.2d).   
Anti-FeLV antibodies.  The majority of cats had low IgG and IgA MFI values for FeLV 
(average MFI of 90 and 77, respectively).   
Estimation of percent FIV-specific IgG antibodies.  Estimates of the percentage of total 
IgG antibodies that are CA- or SU-specific relative to the increase in total IgG antibodies due to 
infection are summarized in Table 4.4.  The range of CA-specific IgG antibodies was 1.3 to 
11.1%, and for SU-specific antibodies was 0.2 to 9.6%.   
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a)             b)  
                                      
 
c)            d) 
                                         
 
Figure 4.2.  Total IgA (a), α-CA IgA (b), α-SUFIV-C IgA (c) and α-CD134 IgA (d) responses for cats from the co-infection study.  Cats 
were inoculated on day -24 with PLV (PLV and CO groups) and/or on day 0 with FIV-C (FIV-C and CO groups).  Data points 
represent the mean MFI + SE.  The dotted horizontal lines represent the level of non-specific antibody binding or the mean MFI + 
2SD for α-Fc IgA antibodies  (MFI 588).  The decrease in IgA for PLV cats at day 17 is likely because three (of five) plasma samples 
were not available for testing; the two cats with samples on day 17 tended to have low IgA values at the other time-points tested. 
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Table 4.4.  Estimates of the percentage of IgG antibodies that are CA- or SU-specific relative to 
the increase in total IgG antibodies due to infection.  These estimates are for the final time-point 
examined in each of the two in vivo studies.  
 
 
 Range of % IgG estimates (median) 
Study/group CA-specific SU-specific 
Co-infection   
FIV-C 1.3-9.6 (3.3) 0.7-9.6 (3.2) 
CO 2.1-11.1 (2.8) 0.2-1.8 (0.9) 
   
Chimera   
*
FIV-C 0.06-1.4 (1.4) 1.4-5.7 (1.4) 
*
FIV-A/C 0.2-1.6 (0.3) 1.5-18.5 (2.5) 
FIV-A 1.6-10.1 (2.2) 6.5-19.8 (10.9) 
 
* 
One cat in the group was excluded because total IgG was below the average total  
  IgG response of the sham cats.   
 
 
Chimera study antibody response.  Total IgG.  The kinetics and level of the total IgG 
antibodies differed among the four treatment groups (p <0.05; Figure 4.3a).  There were 
significant differences in the antibody kinetics of sham cats with both FIV-C and FIV-A/C cats, 
and between FIV-C and FIV-A cats (p-values <0.05).  On average the level of total IgG response 
was higher in FIV-C than FIV-A cats (p <0.05), whereas sham cats had similar IgG levels to 
both FIV-C and FIV-A/C cats.  On average the level of the total IgG response for FIV-A cats 
was lower than both FIV-A/C and sham cats (p-values <0.05), and the FIV-A/C cats were lower 
than FIV-C cats (p <0.01).  The concentrations for total IgG ranged from 3.1 to 29.3 mg/ml.   
Anti-capsid IgG.  The α-CA IgG MFI for individual cats/group means were maximized 
from day 21 through 326 with the current assay conditions (i.e., 1:50 dilution; Figure 4.3b).  
Days 67 and 326 were excluded from statistical analyses because the mean MFIs reported for 
FIV-A and FIV-C cats on day 67 were maximized (i.e., any differences in the antibody response 
that might have occurred at these time-points were not detected).  For days 7 through 35, 
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a)     b)  
                                
  
c)                                                                              d) 
                                
       
Figure 4.3.  Total IgG (a), α-CA IgG (b), α-SU IgG (c) and α-CD134 (d) IgG responses for cats from the chimera study.  Data points 
represent the mean MFI + SE.  The dotted horizontal lines represent the level of non-specific antibody binding or the mean MFI + 
2SD for α-Fc IgG antibodies (MFI 91).  Arrows indicate where the MFI for individual cats/group means were maximized with current 
assay conditions (i.e., using a 1:50 sample dilution). 
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antibody kinetics differed among the four treatment groups (p <0.001).  There were significant 
differences in both the kinetics and level of the antibody response of sham cats with both FIV-C, 
FIV-A/C cats, and between FIV-C and FIV-A/C cats (p-values <0.05).   
Anti-surface IgG.  The α-SU IgG MFI for group means for FIV-C and FIV-A/C cats were 
maximized on day 326 with current assay conditions (i.e., 1:50 dilution; Figure 4.3c).  Day 326 
was excluded from the statistical analyses because any differences in the level of the antibody 
response that might have occurred at this time-point were therefore not detected.  For days 7 
through 67, there was a significant difference in the antibody kinetics among the groups (p 
<0.001).  The kinetics of the three virus-challenged groups were significantly different from 
sham cats (p-values <0.001); however, there were no differences in the antibody kinetics among 
the virus-challenged groups, despite the fact that FIV-A was generally lower over time.  On 
average, the level of α-SU IgG responses for FIV-C and FIV-A/C cats were higher than FIV-A 
cats (p-values <0.01), but FIV-C and FIV-A/C were similar to each other.   
Anti-CD134 IgG.  The α-CD134 IgG data were not analyzed by repeated-measures 
ANOVA because the majority of the values were below the non-specific antibody binding level 
(MFI of 91; Figure 4.3d).  None of the cats, regardless of treatment group, had IgG antibodies 
attributed to CD134 between days 7 through 35.  On day 67, seven cats (three FIV-C and four 
FIV-A/C) had elevated α-CD134 IgG antibodies (MFI range 154 to 3,148).  Although there was 
a statistical difference among the groups at this time-point (p <0.001), there was no difference 
between FIV-C and FIV-A/C cats (i.e., the two groups that had IgG antibodies attributed to 
CD134).  By day 326, four of these seven cats no longer had detectable α-CD134 IgG antibodies, 
and two others had decreased levels.  Only one of the FIV-C cats had an increase in IgG 
antibodies attributed to CD134 from day 67 to 326 (MFI 3,148 to 10,137).  In addition, only one 
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FIV-A cat had detectable α-CD134 IgG antibodies at day 326 (MFI 213).  There were no 
statistical differences among the groups on day 326.   
Total IgA. There were no differences among the treatment groups for total IgA over time 
(range 0.1 to 2.8 mg/ml, average 0.9 mg/ml; Figure 4.4a). 
Anti-capsid IgA.  There was a significant difference among the treatment groups over 
time for α-CA IgA (p <0.05; Figure 4.4b).  There were significant differences in the antibody 
kinetics of FIV-A cats with both sham and FIV-A/C cats (p-values <0.01).  On average the level 
of the α-CA IgA response was higher in FIV-A cats than either sham or FIV-C cats (p-values 
<0.05), and FIV-A/C cats had a higher level than FIV-C (p <0.01). 
Anti-surface IgA.  The α-SU IgA data were not analyzed by repeated-measures ANOVA 
because the majority of the values were below the non-specific antibody binding level (MFI of 
821; Figure 4.4c).  None of the cats had IgA antibodies attributed to SU on day 7 or 14.  From 
day 21 to 67, only 5 samples (of 72) had values above the non-specific antibody binding level; 
four of these were from two FIV-C cats and one from a FIV-A cat (MFI range 862 to 2,081).  On 
day 326, three of the FIV-C cats (MFI range 1,010 to 6,578) and three of the FIV-A cats (MFI 
range 6,164 to 16,389) had detectable IgA antibodies to SU.  Although there was a statistical 
difference among the groups at day 326 (p <0.01), there was no difference between the two 
groups that had an IgA antibody response attributed to SU (i.e., FIV-A and FIV-C cats).   
Anti-CD134 IgA.  None of the cats detectable IgA antibodies to CD134; all values were 
below the non-specific antibody binding level (MFI 821; Figure 4.4d).   
Anti-FeLV antibodies.  The majority of cats had low IgG and IgA MFI values for FeLV 
(average MFI of 9 and 22, respectively).   
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a)    b) 
                                   
  
c)  d) 
                                         
 
Figure 4.4.  Total IgA (a), α-CA IgA (b), α-SU IgA (c) and α-CD134 IgA (d) responses for cats from the chimera study.  Data points 
represent the mean MFI + SE.  The dotted horizontal lines represent the level of non-specific antibody binding or the mean MFI + 
2SD for α-Fc IgA antibodies (MFI 821).
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Estimation of percent FIV-specific IgG antibodies.  Estimates of the percentage of total 
IgG antibodies that were CA- or SU-specific relative to the increase in total IgG antibodies due 
to infection are summarized in Table 4.4.  The range of CA-specific IgG antibodies was 0.06 to 
10.1%, and for SU-specific antibodies was 1.4 to 19.8%.   
DISCUSSION 
This study demonstrates the successful development and validation of MIAs for the 
quantification of feline total IgG and IgA, and for the detection of IgG and IgA antibodies to FIV 
CA and SU proteins, and feline CD134 in domestic cat plasma.  The utility of these assays were 
illustrated by examining the kinetics and level of the IgG and IgA responses in cats 
experimentally infected with various FIV strains (from studies where differences in 
immunopathology and viral kinetics had previously been described (55, 57)).   
The total IgG concentrations obtained for the cats in the two in vivo studies are similar to 
values previously reported for uninfected and FIV-infected domestic cats measured by ELISA 
(1, 29).  In the data reported here, the kinetics and level of the total IgG response varied by FIV 
strain.  The kinetics of the total IgG response for the least virulent viruses (PLV or FIV-A) were 
similar to the respective sham group, whereas the kinetics for the more virulent viruses (FIV-C 
or FIV-C and FIV-A/C) were significantly different from the respective sham group.  In the 
chimera study, the highest IgG antibody response was observed with the FIV-C cats (most 
virulent), followed by FIV-A/C cats and then FIV-A cats (least virulent).  In the co-infection 
study, on average the level of the PLV response was similar to FIV-C cats, but lower than CO 
cats.  These results suggest an additive effect on IgG production with co-infection, in that the 
initial increase in total IgG due to PLV was increased further by the subsequent FIV-C infection.  
In these two studies, the FIV-infected cats (specifically FIV-C and FIV-A/C cats) had increasing 
 77 
levels of total IgG over time; these data support the findings of previous FIV studies, in which 
domestic cats have elevated levels IgG antibodies (1, 29), likely due to ongoing polyclonal B-cell 
activation. 
In the co-infection study, cats infected with PLV developed IgG antibodies that cross-
reacted with the CA protein, but not the SU protein, of FIV-C.  These results are not unexpected 
as the CA proteins of FIV-C and PLV are 64.4% identical at amino acid sites, whereas the SU 
proteins of these two viruses are 19.7% identical at amino acid sites (amino acid sequence 
alignment in Geneious 5.6.6; Biomatters Ltd, Auckland, New Zealand).  Because of this cross-
reactivity, the CO cats had a higher α-CA IgG response than FIV-C cats at early time-points.  It 
is unknown whether the increase in α-CA antibodies prior to FIV-C infection could contribute to 
the observed CD4
+
 T-cell maintenance in the CO cats.  However, the fact that the CO cats 
experienced a transient decrease in peripheral CD4
+
 T-cells, which was similar to the decrease in 
the FIV-C cats at this same time-point, suggests that these antibodies may not be directly 
associated with the overall CD4
+
 T-cell maintenance.  Perhaps, as suggested with HIV, the 
presence of α-CA antibodies are an indicator of the immune system functioning efficiently (7), in 
that CD4
+
 T-helper cells are able to activate B-cells for differentiation into antibody-producing 
plasma cells. 
In the chimera study, the early temporal dynamics observed for the α-CA and α-SU IgG 
responses correspond with the early viral and proviral load dynamics of these cats.  As noted by 
Thompson et al. (2011), FIV-C cats had the highest viral loads, followed by FIV-A/C and then 
FIV-A cats.  The fact that kinetics and level of the rProtein IgG response were similar between 
FIV-A/C and FIV-A cats for CA, and similar between FIV-A/C and FIV-C cats for SU was 
consistent with the corresponding viral proteins expressed by the chimeric virus (i.e., FIV-A/C 
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contains FIV-A gag and FIV-C env genes).  However, it was surprising that there were no 
significant differences between FIV-C and FIV-A cats for both α-CA and α-SU IgG antibodies, 
despite the fact that FIV-A cats generally have lower IgG antibody levels.  The lack of 
significance is perhaps due to the large standard error for the FIV-A cats on days 28 and 35 for 
both α-CA and α-SU IgG antibodies.  Similar to previous studies (9, 47), the results of the 
chimera study demonstrate that antibody kinetics and levels can vary by viral strain; however, 
the results of this study demonstrate that the antibody levels are positively associated with 
virulence.  This would suggest that the viral antigen load contributes to the magnitude of the 
anti-FIV antibody response, versus a situation in which a more robust antibody response 
contributes to a decrease in plasma viral load. 
Similar to findings reported by Grant et al. (31), the IgG antibody response to CD134 
observed here was variable among individuals, and there was a trend for high CD134 antibodies 
associated with lower plasma viral loads among the FIV-C cats in the chimera study.  The two 
FIV-C infected cats that had high levels of α-CD134 IgG antibodies (>1,000 MFI) at day 67, on 
average had lower plasma viral loads from day 173 to 326 (statistical analyses were not 
conducted due to the small sample size, n = 4).  This trend was not observed for FIV-A/C cats, 
which also had α-CD134 IgG antibodies on day 67, or for the FIV-A cats, which regardless of 
viral load, did not have α-CD134 IgG antibodies at this time-point.  It is known that FIV-A 
infected cats can develop α-CD134 IgG antibodies, as 21 of the 24 FIV-Petaluma (clade A virus) 
positive cats in the study by Grant et al. (31) had detectable antibodies at 30 months post-
infection.  Perhaps the period of time needed for the development of α-CD134 IgG antibodies is 
longer with less virulent FIV strains, such as FIV-A (i.e., > 326 days, which was the length of the 
chimera study).  Similar antibody and viral load comparisons were not conducted for the co-
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infection study due to limited plasma viremia data.  Additionally, none of the PLV cats 
developed α-CD134 IgG antibodies.  This is perhaps because of a difference in receptor usage; 
CD134 does not appear to be the sole, primary receptor for PLV cell entry (52).  Despite the fact 
that PLV cats did not develop α-CD134 IgG antibodies, CO cats developed detectable IgG 
antibodies against CD134 earlier after FIV-C infection than the FIV-C single infection group.  
Although a statistical association between α-CD134 IgG antibodies and viral load/clinical 
outcome could not be made, we documented some trends similar to those observed by Grant et 
al. (31). 
Given that FIV-infected domestic cats exhibit elevated levels of total IgG antibodies (1, 
29) and that these antibodies are not entirely virus-specific (26), we estimated the increase in 
total IgG antibodies that were CA- or SU-specific.  The percentage of the total IgG response that 
was estimated to be CA-specific ranged from 0.06 to 11.1% and SU-specific ranged from 0.2 to 
19.8%.  These large ranges may be artifacts of the method used for estimating FIV-specific 
antibodies (i.e., on average, the closest rProtein dilution was ± 936 MFI from the total IgG MFI, 
and the average total IgG response for the sham cats was not necessarily equivalent the total IgG 
baseline level for each FIV-infected cat).  For individual cats from both studies, the estimated 
percentage of antibodies that were FIV-specific (i.e., CA plus SU) ranged from 1.8 to 21.8%.  
However, the total percentage of FIV-specific antibodies would be higher, as domestic cats 
develop antibodies to other viral proteins besides CA and SU (24, 29, 34, 42).  It is unknown 
what the majority of IgG antibodies are directed against or how these values would compare to a 
‘typical’ viral infection.  It would be interesting to obtain similar percentages for non-viral and 
self antigens, as described by Flynn et al. (26), to compare with the percentages obtained here for 
CA and SU proteins.   
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The total IgA concentrations obtained for the cats in the two in vivo studies are similar to 
values previously reported for uninfected and FIV-infected domestic cats measured by ELISA 
(1, 29).  Previous studies have documented normal levels of total IgA in FIV-infected cats during 
the first year of infection (data not shown (29)) and at 24-28 weeks post-infection (1); however, 
elevated levels of total IgA have been noted with a few healthy, FIV-infected domestics cats 
(29).  Nonetheless, neither the co-infection nor the chimera study presented temporal differences 
in total IgA levels.   
In general there were few differences in the IgA antibody response to the rProteins.  The 
most notable, however, was the α-CA IgA response of FIV-A infected cats in the chimera study.  
The differences in antibody kinetics and level of the FIV-A cats to the other groups were due to 
the elevation in α-CA IgA at day 326.  Interestingly, it was also the FIV-A group at day 326 that 
had the highest α-SU IgA response.  These data suggest that either IgA antibodies to the 
rProteins have yet to be developed or are not present/detectable in the periphery during the early 
stage of infection (e.g., within two months post-infection), and that perhaps the observed 
differences in the IgA response among the virus-challenged groups are due to differences in viral 
pathogenicity.  It is possible that cats in the co-infection study developed IgA antibodies to the 
rProteins, but similar to the chimera studies, these antibodies may only be elevated at later time-
points (i.e., after two months post-infection).  Burkhard et al. (9) noted variable levels of IgA 
antibodies to the CA protein between three to nine weeks post-infection; these levels varied 
based on inoculation route, viral strain and among individuals in a treatment group.  
Interestingly, no IgA antibodies were detected against the envelope protein (9).  Grant (1995) 
also noted that some cats developed α-CA IgA antibodies two months after infection, and that 
the number of cats with detectable antibodies varied by FIV strain (data not shown (29)).   
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Although other studies have evaluated antibody response to FIV (1, 9, 10, 24, 26, 29, 31, 
34, 42, 46, 47), the data presented here provides the most comprehensive analysis to date, 
particularly for early stages of infection, and for in vivo studies where viral kinetics and other 
clinical parameters have been well described.  With the MIAs, we were able to detect antibodies 
to multiple analytes simultaneously, in addition to the detection of albumin in each sample.  The 
detection of albumin confirmed that plasma was loaded into each well; this was particularly 
important when target antibodies were not detected (e.g., early time-points before FIV-specific 
antibodies were detectable in plasma).  As demonstrated here, the MIAs are useful for 
characterizing the antibody response over time and studying trends related to disease outcome.   
One limitation of multiplexed MIAs is that a single dilution may not be ideal for 
measuring each of the analytes.  For example, total IgG and IgA were not multiplexed because of 
the difference in dilution required for quantification (i.e., 1:200,000 and 1:10,000, respectively), 
and the 1:50 sample dilution was not ideal for measuring the level of the IgG response for each 
of the analytes in the rProtein assay (i.e., at later time-points the α-CA and α-SU IgG MFI 
maximized).  Given that the relationship between analyte concentration and signal for 
immunoassays are not generally linear (2), the MFI values obtained with different dilutions may 
not be comparable.  Thus, single dilution was used in rProtein experiments in order to compare 
the raw MFI among the groups over time.  To compare differences in the kinetics and level of 
each analyte across all time-points, samples would need to be tested with multiple dilutions (e.g., 
1:50 for CD134, 1:500 for SU, and 1:5,000 for CA); however, this defeats the benefit of using a 
multiplex assay. 
Another potential limitation of the rProtein MIAs is that both IgG and IgA antibodies can 
bind to the recombinant proteins; the only difference between these two assays is that the 
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detection antibodies bind to either IgG or IgA.  Given that the concentrations of total IgG were 
much higher than the concentrations of total IgA in these two studies (IgG was ~3 to 285 times 
higher than the respective IgA value), it is possible that the α-rProtein IgA antibodies were out 
competed by the higher levels of α-IgG rProtein antibodies.  This might contribute to the lack of 
detectable IgA antibodies to the rProteins; however, to be certain this would require the removal 
of IgG antibodies from each plasma sample (e.g., as described in (30)) prior to testing.  Despite 
the above limitations, the rProtein assays would be useful to determine whether a cat has 
detectable α-CA or α-SU antibodies for diagnostic purposes. 
It is unknown how the MIAs compare to conventional immunoassays, such as ELISA or 
immunoblot.  For this reason, as well as others (e.g., different viral strains and time intervals 
examined), we were unable to make direct comparisons to previous studies (e.g., ELISA (9, 10, 
31, 46, 47) or immunoblot (24, 29, 34, 42)).   
Possible functions of FIV-specific antibodies, such as the ones described in this study, 
could include viral neutralization, viral opsonization and/or antibody-dependent cell-mediated 
cytotoxicity (reviewed in (3, 58)).  Given that IgG subclasses have different functional properties 
and that the presence of human IgG subclasses can vary with HIV disease state (reviewed in 
(58)), it would be interesting to compare the kinetics and levels of the three (possibly four) 
domestic cat IgG subclasses (30) throughout FIV infection. 
In summary, the results presented in this study demonstrate that a) total IgG antibodies 
increase over time after FIV infection; b) α-CA and α-SU IgG antibodies are first detectable 
between 9-28 days post-infection and increase over time, and that these antibodies are a fraction 
of the total IgG increase; c) α-CD134 IgG antibody production varies among individuals and 
over time, and was not strongly correlated to viral load during early stage of infection; d) 
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circulating IgA antibodies, in general, do not increase after IV FIV infection; and e) total IgG, 
and α-CA and α-SU IgG antibody kinetics and level vary with FIV viral strain/pathogenicity 
(Figure 4.5).  In future studies, the total IgG and IgA MIAs described here could be used to 
evaluate the antibody response of elicited by a variety of diseases in domestic cats, and the 
rProtein MIAs could be used to evaluate the domestic cat antibody response elicited by other 
FIV strains or to screen samples for FIV and/or FeLV infection.  These assays could be 
expanded to include other antibodies (e.g., IgM, IgG subtypes), additional viral proteins (e.g., 
TM or specific FIV protein epitopes) or adapted to test other samples types, such as saliva.  
Assays such as these will be useful for assessing the IgG and IgA response associated with 
disease pathogenesis and/or protective vaccine immunity.   
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Figure 4.5.  Summary of the peripheral/circulating antibody response during the early stage of FIV-single and co-infection.  For FIV-
single infected cats [FIV-C, FIV-A and FIV-A/C cats]: (a) the total antibody concentration ranged from 3.1 to 35.8 mg/ml for IgG, 
and 0.1 to 7.5 mg/ml for IgA; (b) the IgG antibody response to CD134 varied greatly among individuals/over time, but was mostly 
detected around 66 days post-infection; (c) the percentage of total IgG antibody increase that was estimated to be CA-specific ranged 
from 0.06 to 10.1%, and SU-specific ranged from 0.7 to 19.8%; and (d) the kinetics and level of the IgG response varied by FIV 
virulence.  For co-infected cats: (a) the total antibody concentrations ranged from 12.1 to 45.4 mg/ml for IgG, and 0.6 to 3.6 mg/ml for 
IgA; (b) the antibody response for total IgG and α-CA IgG antibodies were higher during the early stage of FIV infection due to prior 
infection with PLV [the α-SU IgG and α-CD134 IgG responses were similar between single (high virulence) and co-infected cats]; 
and (c) the percentage of total IgG antibody increase that was estimated to be CA-specific ranged from 2.1 to 11.1%, and SU-specific 
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APPENDIX 
Baculovirus protein expression.  Surface and transmembrane proteins.  FIV env 
encodes an envelope polyprotein (140-150 kDa), which contains an L-domain, and SU and TM 
proteins (54, 61).  After translation, the glycosylated polyprotein undergoes two cleavage steps; 
the first cleavage step removes the L-domain (20 kDa), which contains the secretion signal 
required for protein transport outside the cell (53), and the second cleavage step separates the SU 
(gp95) and TM (gp40) proteins (54, 61).  Since the SU and TM proteins are glycosylated and a 
secretion signal is required for transport outside of the cell, we attempted to express these 
proteins in insect cells using an insect cell secretion signal. 
Honeybee melittin signal sequence.  The honeybee melittin (HBM) signal sequence (63 
nucleotides), was selected because it has been shown to enhance foreign protein secretion from 
insect cells ((56); however, protein secretion with HBM may be equivalent to the native 
sequence signal (36)).  To generate a dsDNA HBM sequence, complementary oligonucleotides 
of the HBM sequence (Integrated DNA Technologies, Coralville, IA) were annealed using a 
touchdown PCR protocol.  The sequences included additional 5’ and 3’ nucleotides for 
directional insertion into the plasmid, to eliminate the need for restriction enzyme digestion 
(Table 4.5).   
The FastBac Dual plasmid (pFBD; Life Technologies; provided by D. Henderson) used 
for protein expression has ampicillin and gentamicin resistance genes for plasmid and bacmid 
selection, respectively.  Purified plasmid was digested with BamHI and EcoRI restriction 
enzymes, and ligated with the dsDNA HBM sequence using T4 DNA ligase according to 
manufacturer recommendations (New England BioLabs).  The plasmid was propagated in One 
Shot
®
 TOP10 Chemically Competent E. coli according to manufacturer recommendations (Life  
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Table 4.5.  Primers used for the amplification of SU and TM nucleotide sequences, and sequencing of plasmid and bacmid inserts, as 
well as the complementary honeybee melittin (HBM) oligonucleotide sequences.  Restriction sites (underlined), His-tags (bolded), 
start codons (italicized) and stop codons (wave underlined) incorporated into the primers/oligonucleotides are noted.   
 
Primer/oligonucleotide 
(Restriction site, tag) 
Sequence 
(5’-to-3’) 
Baculovirus expression  
     SU (EcoRI, 6-His) Fwd CCGGAATTCCATCACCATCACCATCACAGACTCCCACCCTTAGTAGTC 
     SU (PstI) Rev AACTGCAGCTACTATCTTTTTTGTCTTGATTGATAGTTTAAAACTTCTT 
     TM (EcoRI, 6-His) Fwd CCGGATTCCCATCACCATCACCATCACACCCAATATCATCAAGTCCTAGCTA 
     TM (PstI) Rev AACTGCAGCTACTATTTTCCCATCCATCCCGTC 
     pFBD Fwd CGTAACAGTTTTGTAATAAAAAAACCTATAAATATTCC 
     pFBD Rev CCTCTACAAATGTGGTATGGCTG 
     Bacmid Fwd GTTTTCCCAGTCACGAC 
     Bacmid Rev CAGGAAACAGCTATGAC 
     HBM (BamHI
a
) Fwd GATCCACCATGAAATTCTTAGTCAACGTTGCCCTTGTTTTTATGGTCGTATACATTTCTTACATCTATGCGGCCG 
     HBM (EcoRI
a
) Rev AATTCGGCCGCATAGATGTAAGAAATGTATACGACCATAAAAACAAGGGCAACGTTGACTAAGAATTTCATGGTG 
  
E. coli expression  
     SU (BamHI) Fwd CGCGGATCCATGAGACTCCCACCCTTAGTAGTCCCA 
     SU (EcoRI) Rev CCGGAATTCCTACTATCTTTTTTGTCTTGATTGATAGTTTAAAACTTCTTCTGGTACC 
     TM (BamHI) Fwd CGCGGATCCATGACCCAATATCATCAAGTCCTAGCTACTCATCAA 
     TM (EcoRI) Rev CCGGAATTCCTACTATTTTCCCATCCATCCCGTCCAATATTCC 
 
a




Technologies).  Purified plasmid was sequenced (Proteomic and Metabolomics Facility, 
Colorado State University) to confirm HBM insertion using the pFBD primers (Table 4.5). 
 Surface and transmembrane nucleotide sequences.  Sequences encoding SU and TM 
were amplified from a molecular clone of FIV-C (19) using standard PCR protocols.  Based on 
an alignment of FIV-C with other annotated FIV strains (10, 37, 39, 45), the segment amplified 
for SU was 6,808 to 8,097 (1,290 nucleotides) and for TM was 8,182 to 8,601 (420 nucleotides).  
The coding region for TM excludes the hydrophobic region (N-terminus), and intracellular and 
hydrophobic transmembrane domain (C-terminus); these regions were excluded because 
hydrophobicity could affect protein solubility and/or secretion, and the inter-cellular region is not 
exposed to neutralizing antibodies.  The primers, which included restriction sites for directional 
insertion into the plasmid and polyhistidine (6-His) tags, are listed in Table 4.5.  Purified PCR 
products were digested with EcoRI and PstI restriction enzymes according to manufacturer 
recommendations (New England BioLabs), and stored at -20°C until ligation with the HBM-
pFBD plasmid. 
The HBM-pFBD purified plasmid was digested with EcoRI and PstI restriction enzymes, 
and ligated with the SU or TM sequence using T4 DNA ligase according to manufacturer 
recommendations (New England BioLabs).  The plasmid was propagated in One Shot
®
 TOP10 
Chemically Competent E. coli according to manufacturer recommendations (Life Technologies).  
Purified plasmid was sequenced (Proteomic and Metabolomics Facility, Colorado State 
University) to confirm SU or TM insertion using the pFBD primers (Table 4.5). 
Protein expression.  DH10Bac
™
 E. coli (Bac-to-Bac
®
 Baculovirus Expression System, 
Life Technologies; provided by D. Henderson) were transformed with SU-HBM-pFBD or TM-
HBM-pFBD according manufacturer recommendations.  DH10Bac
™
 E. coli contains a helper 
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plasmid and a baculovirus shuttle vector (bacmid); the helper plasmid supplies proteins required 
for transposition of the recombinant protein sequences into the bacmid.  Recombinant bacmid 
DNA was isolated according to the manufacturer recommendations (Life Technologies).  To 
confirm the insertion of SU- or TM-HBM into the bacmid, the region spanning the transposition 
site was amplified by PCR using bacmid primers (Table 4.5).  On an agarose gel, a band ~3,000 
bp suggested that TM-HBM was inserted into the bacmid, and a band ~ 4,000 bp suggested that 
SU-HBM was inserted into the bacmid. 
The bacmids were then used to transfect Sf9 insect cells (Spodoptera frugiperda or fall 
armyworm cell line; provided by D. Henderson) according to the manufacturer recommendations 
(Life Technologies).  Cells were incubated at 28°C in Sf-900 II media (Life Technologies) with 
penicillin/streptomycin and fungizone.  Cells were monitored daily for cytopathic effect (CPE; 
e.g., increased diameter, granular appearance and lysis) and passaged according to manufacturer 
recommendations.  Briefly, transfected cells were initially grown in 6-well tissue culture plates 
for four days.  The supernatant from these cells were then transferred to 10 cm plates (passage 1) 
containing 10
7 
Sf9 cells and incubated for 72 hours.  The supernatant from one SU and one TM 
culture was then transferred into a flask (passage 2) containing 1.5x10
6 
cells/ml in 250 ml of Sf9 
media, and incubated for an additional 72 hours.   
Both the supernatant and the cells from passages 1 and 2 were tested by SDS-PAGE and 
immunoblot (α-His antibody) for the presence of SU and TM proteins.  There were no visible 
bands in the supernatant or cells around the expected molecular weights for SU or TM 
expression (>51 and >18 kDa, respectively; weights expected to be above the kDa listed due to 
glycosylation).  Multiple experiments were conducted to trouble-shoot the protein expression, 
such as repeating the transfection of Sf9 cells, modifying the immunoblot protocol (e.g., primary 
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antibody incubation time, antibody diluent and using a different α-His antibody), and using an 
alternative method for protein purification (i.e., fast protein liquid chromatography).  Despite 
these efforts, SU and TM proteins were never identified/purified.  Possible reasons for the lack 
of protein expression include bacmid DNA degradation (e.g., perhaps due to storage at 4°C from 
time of isolation until transfection), low transfection efficiency and/or sub-optimal growth 
conditions (e.g., temperature or incubation times).  Additionally, it is possible that the HBM 
sequence did not enhance expression/secretion in the baculovirus system (36) or that there was 
an error with the SU- or TM-HBM insertion that prevented protein expression (e.g., frame-shift 
that affected translation).  Due to time limitations, no additional baculovirus expression 
experiments were conducted. 
E. coli protein expression.  Because the baculovirus expression of SU and TM was 
unsuccessful, an attempt was made to express these proteins in E. coli.  The primers used to 
amplify the SU and TM regions are listed in Table 4.5.  The protocols and regents used were 
identical to those described for the recombinant FIV-C CA protein (see above).  However, unlike 
the CA expression, when the purified protein solution was run on a SDS-PAGE gel, there were 
no visible bands at the expected molecular weights for SU or TM (~51 and ~18 kDa, 
respectively).  Upon examination of the respective cell pellets, a band was noted at the molecular 
weight of SU-GST (~77 kDa) or TM-GST (~44 kDa).  These results suggested that perhaps the 
reagent used to lyse the cells was inefficient or that the recombinant proteins were in inclusion 
bodies.  Additional protein expression experiments using a different lysing reagent, suggested 
that the band ~77 kDa was a bacterial protein (i.e., not SU-GST), whereas the band ~44 kDa was 
TM-GST.  It is possible that the SU protein was expressed at low levels, but not visible by SDS-
PAGE because it was masked by a bacterial protein or that culture conditions were not optimal 
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for expression.  Due to time limitations, no additional experiments were conducted to determine 
why the SU protein did not appear to be expressed (e.g., immunoblot or optimizing culture 
conditions, such as media, incubation time or temperature) or to remove the TM protein from the 
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CHAPTER 5:  DEVELOPMENT OF REAL TIME PCR ASSAYS FOR THE 





Feline immunodeficiency viruses (FIVs) are naturally occurring lentiviruses (RNA 
genome; family Retroviridae) of felids, including the domestic cat (Felis catus) and at least 10 
species of free-ranging wild cats (4, 9).  Each felid species is typically infected with a 
genetically-distinct FIV strain (9); however, mountain lions (Puma concolor; also referred to as 
cougar, panther or puma) can be infected with two distinct strains ((2, 4), Lee et al., 
unpublished).  Free-ranging and captive mountain lions are infected with FIVPcoB or puma 
lentivirus (PLV)-B throughout their geographic range in North and South America ((2, 4), Lee et 
al., unpublished).  In California and Florida, free-ranging mountain lions are infected with 
FIVPcoA or PLV-A, which is highly divergent from PLV-B ((2, 4), Lee et al., unpublished).  
Interestingly, bobcats (Lynx rufus) are also infected with PLV-A; PLV-A has been detected in 
bobcats from California and Florida, but not Colorado ((4, 6), Lagana et al., in press and Lee et 
al., unpublished).  To date, PLV-A is the only FIV sequenced from bobcats ((4, 6), Lagana et al., 
in press and Lee et al., unpublished). 
Given that a) PLV-A is the only known FIV to infect bobcats, b) PLV-A is less common 
in mountain lions than PLV-B, and c) PLV-A in mountain lions has only been reported in 
geographic regions with PLV-A infected bobcats, Franklin and Troyer et al. (4) hypothesized 
that PLV-A may actually be of bobcat origin, and that PLV-A in the mountain lion is the result 
of cross-species transmission events.  Analyses of PLV-A proviral sequences support this 
                                                        
4
 Ryan M. Troyer and Sue VandeWoude contributed to the research presented in this chapter. 
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hypothesis, in that viral isolates from mountain lions were more likely to be undergoing positive 
selection than bobcat viral isolates (Lee et al., unpublished).  Additionally, preliminary data 
indicates that bobcats have significantly higher PLV-A proviral loads than mountain lions  
(p <0.01; Templin-Hladky et al., unpublished), suggesting that PLV-A replicates less efficiently 
in mountain lions.  However, as provirus indicates a residual infection, the detection of viral 
RNA would be a more accurate measure of viral fitness.  Thus, the aim of this project is to adapt 
the PLV proviral quantitative PCR (qPCR) assays (Templin-Hladky et al., unpublished) for the 
quantification of viral RNA in plasma.  Since domestic cat cross-species infection studies 
indicate that non-host adapted FIVs (e.g., PLV-A, PLV-B or lion lentivirus (FIVPle)) typically 
result in lower levels of plasma viremia than host-adapted FIV strains (11, 12), we predict that 
mountain lion PLV-A viremia will be lower than bobcat PLV-A and mountain lion PLV-B 
viremia. 
MATERIALS AND METHODS 
Plasma samples.  Blood samples were collected from free-ranging bobcats and mountain 
lions in California, Colorado and Florida (2002 to 2011), as part of ongoing research projects 
conducted by our laboratory and collaborators.  Appropriate approvals were obtained prior to the 
collection of samples.  Plasma was separated from each blood sample as previously described 
(5), and stored at -80°C.   
The plasma samples used thus far for assay development were from PLV-A positive 
bobcats (n = 7) and PLV-B positive mountain lions (n = 14) (Table 5.1); these samples are all 
positive based on provirus sequence data (Lee et al., unpublished).  To date, no PLV-A positive 
mountain lion samples have been tested.  Plasma samples from PLV-A positive mountain lions 
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Table 5.1.  PLV-positive bobcat and mountain lion plasma samples tested to date.  Only four PLV-B samples have viral RNA levels 
above the assay LLOQ (i.e., above 17,000 copies/ml of plasma).  Values reported for PLV-A and PLV-B viremia below the assay 





















(RNA copies/ml plasma) 
PLV-B viremia 
(RNA copies/ml plasma) 
599R1 Lru F A CA Boyce + A 8,400 ND
f
 
603 Lru M A CA Boyce + A 4,300 ND 
1133 Lru M A FL McBride - A 4,900 ND 
1134 Lru M A FL McBride - A 14,000 ND 
1142 Lru M A FL McBride + A 10,000 ND 
1187 Lru M A FL McBride - A 2,100 ND 
1206 Lru M A FL McBride - A 2,100 ND 
85 Pco M A CA Boyce + B ND ND 
88 Pco F A CA Boyce + B ND ND 
92 Pco F A CA Boyce + B 2,200 ND 
121 Pco F A CA Boyce + B ND 3,300 
122 Pco M A CA Boyce + B ND 120,000 
139R1 Pco M A CO Logan + B ND 5,000 
431 Pco F A CO Logan + B ND 30,000 
686 Pco M A CO Logan + B ND 13,000 
1045R1 Pco M A CO Alldredge - B ND 12,000 
1058 Pco F A CO Logan + B ND 6,900 
1077 Pco F Y CO Alldredge + B ND 26,000 
1346R1 Pco F A CO Alldredge + B 860 4,700 
1377 Pco M - CO Logan + B ND 130,000 




 Lru – bobcat (Lynx rufus); Pco – mountain lion (Puma concolor)  
b
 Y – young  (6 months to 2 years); A – adult (≥ 2 years) 
c
 CA – California; CO – Colorado; FL – Florida 
d
 Antibodies to PLV detected by western blot (VandeWoude laboratory) 
e
 Provirus sequenced by J. Lee (unpublished); DNA was extracted from whole blood or peripheral blood mononuclear cells  
f
 ND – Non-detectable 
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will only be tested once assay development is complete, as these samples are more limited in 
number.  Plasma samples from naïve domestic cats served as negative controls for each set/batch 
of RNA extractions and subsequent qPCR experiments.  
Ideally, each sample should remain frozen until viral RNA purification, as repeated 
freeze-thaws can reduce viral titers (QIAmp viral RNA mini kit handbook; Qiagen, Valencia, 
CA).  It is unknown how many freeze-thaws the selected bobcat and mountain lion samples have 
undergone prior to RNA purification.  
Viral RNA extraction.  RNA was extracted from bobcat or mountain lion plasma using 
the QIAmp viral RNA mini kit (Qiagen) according to manufacturer recommendations.  The 
volume of plasma used for each RNA extraction was 140 μl, with the exception of one sample 
that only had 110 μl.  Purified RNA was eluted in 60 μl of AVE buffer (Qiagen) and stored at     
-80°C.   
cDNA synthesis.  Equal volumes of RNA and cDNA master mix were used for cDNA 
synthesis.  For 10 μl of purified RNA, the 10 μl of cDNA master mix consisted of the following: 
4 μl of 5x First Strand Buffer (Life Technologies, Grand Island, NY), 1 μl of 10 mM dNTP (Bio-
Rad, Hercules, CA), 1 μl of 0.1 M DTT (Life Technologies), 0.25 μl of 40 U/μl RNase Out™ 
(Life Technologies), 0.25 μl of 200 U/μl SuperScript
®
 II Reverse Transcriptase (Life 
Technologies), 2 μl of 300 ng/μl Random Primers (Life Technologies), and 1.5 μl of nuclease-
free water.  Samples were incubated at 42°C for 50 min, followed by 95°C for 5 min.  cDNA 
was stored at -20°C until testing in the qPCR assays.   
Primers.  Primers (Templin-Hladky et al., unpublished) used in these experiments are 
listed in Table 5.2.  PLV-A primers amplify a conserved region of env (103 nucleotides), while 
the PLV-B primers amplify a conserved region of gag (151 nucleotides).  These regions were 
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selected for amplification because of conserved regions at both ends for primer binding.  The 
conserved regions were identified by aligning 24 full-length PLV-A sequences (23 unpublished 
sequences from J. Lee and one sequence from GenBank: U0398) or 39 full-length PLV-B 
sequences (26 unpublished sequences from J. Lee, and the following 13 sequences from 
GenBank: DQ192583, EF455603, EF455604, EF455605, EF455606, EF455607, EF455608, 
EF455609, EF455610, EF455611, EF455612, EF455613, EF455615). 
 
Table 5.2.  Primers used to quantify PLV RNA loads. 
Primer Sequence (5’ to 3’) 
PLV-A Fwd GCAGCCCTGACGGTATCC 
PLV-A Rev GCAGTCTCCTCTGAACAATCC 
PLV-B Fwd CTGTCTGTCATGGGGAATGAGT 
PLV-B Rev GTCCTGTAGCTACCAAGGCAA 
 
 
Plasmid standards.  Extracted DNA from the whole blood of a PLV-A positive bobcat 
(cat 188) and a PLV-B positive mountain lion (cat 85), known to contain the conserved env and 
gag primer binding sites, respectively, were used to amplify fragments of these genes for 




 vector (Life Technologies; Templin-Hladky et al., 
unpublished).  The purified plasmids were diluted in TE buffer (10 mM Tris, 1 mM EDTA), and  
concentrations were determined using a NanoDrop spectrophotometer (Templin-Hladky et al., 
unpublished).  Plasmid standards were stored at -20°C. 
Quantitative PCR.  The protocol used initially for the quantification of viral RNA loads 
was identical to the protocol used for proviral quantification (Templin-Hladky et al., 
unpublished).  Briefly, each reaction (25 μl) contained 12.5 μl SsoFast™ EvaGreen
®
 Supermix 
(Bio-Rad), 1 μl the Fwd primer (10 μM), 1 μl the Rev primer (10 μM), 5.5 μl of nuclease-free 
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water and 5 μl of sample cDNA.  Amplification was as follows: 95°C for 30 sec, followed by 40 
cycles of 95°C for 5 sec and 62°C for 10 sec.  To assess amplification specificity, all reactions 
underwent a melt-curve analysis (65°C to 95°C in 0.5°C increments, 10 sec per increment).  The 
iQ5 iCycler (Bio-Rad) used for these experiments was calibrated monthly, and the iQ5 Optimal 
System Software Version 2.0 was used for data collection and analysis.  All standards, no 
template controls and samples (PLV-positive samples (Table 5.1) and naïve domestic cat 
samples) were run in triplicate.  The mean starting quantity (SQ) per sample (mean copies/well) 
was used to calculate the viral RNA copies/ml of plasma.  The equation used for these 
calculations was as follows: 
(SQ) (1/C) (D) (E) (1/P) = RNA copies per ml of plasma 
SQ:  Mean starting quantity per sample 
C:  cDNA volume (μl) added per well of the qPCR assay (5 μl) 
D:  Inverse of the dilution used for cDNA synthesis (e.g., for 1-in-2 dilution D equals 2) 
E:  Elution volume (μl) used for viral RNA extraction (60 μl) 
P:  Plasma volume (ml) used for viral RNA extraction (generally, 0.14 ml) 
All calculated values of RNA copies/ml of plasma were rounded to two significant digits based 
on the precision of the method.  Samples were considered positive when at least two of the three 
replicates had Ct values.   
Assay development.  Lower limit of quantitation.  The initial experiments conducted 
were to determine the lower limit of quantitation (LLOQ) of each assay; although the same 
standards and primers were used for proviral quantification (Templin-Hladky et al., 
unpublished), the LLOQ of both assays had not been investigated.  To determine the LLOQ of 
each assay, PLV-A and PLV-B standards (diluted in TE buffer) were tested on multiple days to 
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plasmid copies/well (10-fold dilution), as well as values below this range, 
such as 10,
 
20, 40, 50, 60 and 80 copies/well.  The lower limit that was reliably quantified in 
these experiments was 10
2
 copies/well for both assays; the Ct values for copy numbers below 10
2 
were no longer linear (i.e., the values overlapped, regardless of concentration).  Using the 
equation noted above, an LLOQ of 10
2
 copies/well is equivalent to 17,143 RNA copies/ml of 
plasma, which rounded to two significant digits is 17,000 RNA copies/ml plasma. 
Bobcat and mountain lion viral RNA loads.  To determine the range of viral RNA loads 
of naturally infected bobcats and mountain lions, we tested plasma samples from PLV-A or 
PLV-B positive cats (n = 21; Table 5.1).  All samples were tested in both assays (PLV-A and 
PLV-B) to confirm that the primers/assays were specific (i.e., based on the sequencing data 
obtained by Lee et al., unpublished). 
All of the PLV-A bobcat samples (7 of 7) had detectable levels of PLV-A RNA (Figure 
5.1); however, these values were below the LLOQ.  None of these bobcats had detectable levels 
of PLV-B RNA.  Given that PLV-A is the only known FIV to infect bobcats ((4, 6), Lagana et 
al., in press and Lee et al., unpublished), these results suggest that the PLV-B primers are 
specific and do not cross-react with PLV-A. 
Four (of 14) of the PLV-B mountain lion samples had viral loads above the LLOQ; these 
values ranged from 26,000 to 130,000 RNA copies/ml of plasma (Figure 5.1).  These plasma 





 RNA copies/ml; (1)).  PLV-B RNA was not detected in three (of 14) 
mountain lion samples (Table 5.1) despite the fact the PLV-B provirus was sequenced from these 
cats (Lee et al., unpublished).  This suggests that either the virus was not actively replicating  
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Figure 5.1.  Detectable plasma viral RNA loads of PLV-A provirus positive bobcats and PLV-B 
provirus positive mountain lions.  The solid lines indicate the medians, and the dashed line 
indicates the lower limit of quantitation (LLOQ; 17,000 copies) for both of the qPCR assays. 
 
 
when the blood samples were collected or that the viral RNA levels were below the assay limit 
of detection.   
In addition, two (of 14) mountain lions had detectable levels of PLV-A RNA (Table 5.1 
and Figure 5.1).  Given that mountain lions can be infected with PLV-A and/or PLV-B ((2, 4), 
Lee et al., unpublished), it is possible that these cats are co-infected with both viruses.  However, 
as one of these cats was captured in Colorado (a region in which PLV-A has not been previously 
detected in either bobcats or mountain lions), it seems unlikely that this cat was infected with 
PLV-A.  (Note: The other PLV-A positive sample was collected in California).  To date, only 
mountain lions in California and Florida are known be infected with PLV-A ((2, 4), Lee et al., 
unpublished).  It is possible that these two PLV-A RNA positive samples could have been 
contaminated (e.g., at blood collection, plasma separation, RNA extraction or qPCR) or that the 
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PLV-A primers cross-react with PLV-B.  However, the latter seems less likely, as one of the two 
mountain lions with PLV-A had undetectable levels of PLV-B viremia (cat 92). 
Overall, these preliminary results suggest that PLV RNA levels for both bobcats and 
mountain lions are within a similar range to those reported for PLV-B positive mountain lions 
(1).  However, due to differences in methods, the majority of the samples tested here are below 
the LLOQ of our assays.  The notable differences between our method and that used by Blake et 
al. (1) are the standard curve range and the plasma sample volume.  The standard range used by 




 copies, with 3.2x10
2 
 being set as their lower limit of 
detection, and the volume of plasma used ranged from 100 μl to 6.5 ml.  By using larger sample 
volumes, and therefore presumably higher starting quantities of viral RNA, the results for the 
majority of samples in the study by Blake et al. (1) were above their limit of detection (i.e., 21 of 
24 samples with reported values).   
Assay modifications.  Given that the majority of the samples tested (17 of 21) had values 
below the assay LLOQ, experiments were conducted to try to lower the LLOQs.  Assay 
modifications were conducted in the following order: (i) addition of carrier nucleic acid to the 
standard curve, (ii) optimization of primer annealing temperature, and (iii) increase in the 
volume of cDNA added per well.   
Yeast tRNA (Life Technologies) was added to the standard diluent (TE buffer) as a 
carrier.  Carrier nucleic acids are added to standard curves to prevent the target nucleic acid (e.g., 
plasmid) from adhering to tube walls (7).  The addition of a carrier can improve the reliability of 
standard detection, particularly at low concentrations (i.e., increasing the linear range of the 
standards (7)).  The concentrations of yeast tRNA tested were 5, 10, 20 or 50 ng/μl; these 
concentrations were selected based on the range of carrier concentrations previously reported for 
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40, 60 and 80 plasmid copies/well.  The addition of 5, 10 and 20 ng/μl yeast tRNA did not lower 
the LLOQ (i.e., Ct values of the standards overlapped below 100 copies/well, regardless of yeast 
tRNA concentration).  With 50 ng/μl of yeast tRNA, the relationship between standard 
concentration and Ct value was no longer linear over the full-range of standards.  Although the 
addition of yeast tRNA at 5, 10 and 20 ng/μl did not improve or hinder plasmid quantification, 
we selected the 10 ng/μl (middle value) as the concentration to be added to the standards for all 
subsequent experiments.   
Next, we optimized the primer annealing temperatures to improve assay performance 
(i.e., improve the standard curve amplification efficiencies and R
2 
values).  The annealing 
temperatures were optimized for the proviral assays by conventional PCR (Templin-Hladky et 
al., unpublished); however, as the efficiency of the PLV-B standard curve tended to be low (i.e., 
values at or below the acceptable range of 90-105%; Real-Time PCR Application Guide, Bio-
Rad), we decided to conduct an additional annealing temperature optimization experiment.  




 copies/well) were tested at eight different temperatures 
(range 52 to 62°C) using the temperature gradient function on the real-time instrument.  For both 
assays, lower annealing temperatures (52, 52.8 and 54.1°C) resulted in higher standard curve 
efficiencies and R
2
 values.  Given that the efficiency and R
2
 values were similar amongst the 
three lowest annealing temperatures, we selected the middle temperature (52.8°C) as the 
annealing temperature for all subsequent experiments.   
Despite the addition of yeast tRNA and lowering the annealing temperature, the LLOQs 
remained at 100 copies/well.  Thus, we decided to increase the amount of cDNA added into each 
reaction (i.e., doubling the volume of cDNA added to each well by replacing 5 μl of nuclease-
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free water with an additional 5 μl of cDNA).  In theory, with this modification, more sample 
values should come above each assay LLOQ.  However, the SQ values reported for these 
samples were not reliable, as the increase in cDNA volume resulted in non-exponential 
amplification curves.  The samples amplified between 10-15 cycles, plateaued between 15-30 
cycles and then amplified between 30-40 cycles.  The reason that the amplification curves 
plateaued between 15-30 cycles is not known.  It is possible that one of the reagents used for 
cDNA synthesis inhibits PCR amplification in a concentration-dependent manner.   
FUTURE DIRECTIONS 
The following assay modifications could be conducted in an attempt to accurately 
quantify PLV-A and PLV-B in plasma samples that have concentrations near/below the LLOQ 
of the current method: (i) purifying the cDNA to eliminate substances that may have inhibited 
PCR amplification (e.g., with QIAquick PCR Purification kit (Qiagen)) and then doubling the 
cDNA volume, (ii) increasing the starting volume of plasma used for viral RNA extraction (i.e., 
up to 560 μl of plasma can be used for RNA extraction), (iii) using different primers, (iv) using a 
different qPCR master mix, and/or (v) using a different type of carrier nucleic acid (e.g., E. coli 
tRNA).  Although increasing the plasma volumes would be the easiest modification, this will 
only be done as a last resort because sample volumes are limited.  In addition to these 
modifications, we need to establish PLV-A and PLV-B positive controls to use with each 
experiment.  Ideally, these controls would be used in each RNA extraction experiment and 
subsequent qPCR assays; however, as plasma volumes are limited, the positive controls might 
only be used in the qPCR assays.   
Once assay development and validation are complete, the plasma samples listed here will 
need to be re-tested using the updated assay conditions.  Additional samples will also need to be 
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tested (e.g., plasma samples from PLV-A positive mountain lions, as well as additional samples 
of PLV-B positive mountain lions and PLV-A positive bobcats) in order to determine whether 
mountain lion PLV-A viremia is lower than bobcat PLV-A and mountain lion PLV-B viremia.  
These results could add further support to the hypothesis proposed by Franklin and Troyer et al. 
(4) that PLV-A is of bobcat origin, and has been transmitted to mountain lions.  In addition, the 
assays described here could be used to (i) screen samples of unknown PLV status for evidence of 
infection (i.e., actively replicating virus), (ii) differentiate PLV-A and PLV-B infections in 
mountain lions, (iii) assess viral kinetics of individual cats (i.e., repeated samplings), and/or (iv) 
examine the PLV strain(s) circulating in Florida panthers before and after the introduction of 
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CHAPTER 6:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
Studies on feline immunodeficiency viruses (FIVs) are beneficial for understanding viral 
pathogenesis and the host immune response associated with lentivirus disease progression (e.g., 
domestic cat FIV), and for understanding viral kinetics and molecular ecology associated with 
naturally occurring infections in wild felids (e.g., bobcats and mountain lion FIVs).  However, 
the lack of feline-specific assays has hampered thorough investigations in these research areas.  
Thus, a goal of the research described here was to develop and validate microsphere 
immunoassays (MIAs) for the evaluation of the domestic cat immune response, and quantitative 
PCR assays for the evaluation of bobcat and mountain lion viral RNA loads.  
The advantage of developing MIAs to evaluate the domestic cat immune response, 
compared to traditional immunoassays, is that multiple analytes can be detected/quantified 
simultaneously, meaning that less time and sample volume are required (reviewed in (18)).  
Currently, 80 different analytes could be detected within a single sample simultaneously using 
the magnetic microspheres and instrument described in this dissertation.  These assays can be 
used with a variety of sample types, including cell culture supernatant (Chapter 2), tissue 
homogenates (1, 6), plasma (Chapters 3 and 4) and other fluids, such as saliva (5, 16) or urine 
(14, 17).  Multiplex MIAs can only be developed as long as there is no cross-reactivity among 
analytes and that the analytes are present in concentrations of a similar order of magnitude.  For 
example, total IgG and IgA could not be multiplexed because of the difference in dilution 
required for quantification (Chapter 4).  Nonetheless, MIAs are a powerful new technology to 
evaluate multiple analytes within biological samples and are relatively easy to develop.   
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In Chapters 2 and 3, we developed, validated and demonstrated the use of cytokine MIAs 
for the quantification of interferon gamma (IFN), interleukin (IL)-10, IL-12/23 in cell culture 
supernatant and plasma.  The results of these experiments indicated that cytokine secretion 
and/or detection varies both among and between sample types, and that mRNA cytokine 
expression may not correlate with secreted protein levels.  Future use of these assays could 
include establishing the normal range of cytokines for domestic cats, or evaluating the cytokine 
response elicited by a variety of pathogens, disease states (e.g., cancer or inflammation), 
vaccines or therapies.  To provide a more complete understanding of the domestic cat cytokine 
response, the MIAs could be expanded to include additional cytokines for which reagents are 
commercially available, such as IL-1, IL-2, IL-4, IL-5, IL-6 and/or tumor necrosis factor alpha.  
In Chapter 4, we developed, validated and demonstrated the use of antibody MIAs for the 
quantification of total IgG and IgA in plasma, and for the detection of IgG and IgA antibodies to 
feline CD134, and FIV capsid (CA) and surface (SU) proteins in plasma.  The results from these 
experiments demonstrated that the kinetics and/or level of the antibody response can vary by FIV 
strain/pathogenicity.  Future use of these assays could include evaluating the antibody response 
generated with the FIV vaccine and/or in various FIV-infection studies, as well as evaluating the 
total antibody response of domestic cats generated by a variety of pathogens, disease states, 
vaccines or therapies.  To provide a more complete understanding of the antibody response to 
FIV, the MIAs could be expanded/modified to include different capture proteins (other viral 
proteins or specific epitopes), to detect different antibodies (IgM or IgG subclasses), and/or to 
test additional sample types (mucosal secretions, such as saliva).  Additionally, a MIA could be 
developed as a surrogate for FIV neutralization, using methods similar to those previously 
described for other viruses (2, 4).  For example, the level of antibodies to particular regions of 
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the FIV SU protein (such as the V4 and V5 regions, which are involved with neutralization (11-
13, 20)) could be positively correlated with virus neutralization titers (as demonstrated with 
equine arteritis virus (4)).  Alternatively, the presence of FIV neutralizing antibodies in a sample 
could be measured indirectly, as the percent inhibition of soluble CD134 binding to the SU 
protein attached to microspheres (as demonstrated with Nipah and Hendra viruses (2)). 
With modifications and/or additional experiments, the MIAs described in this dissertation 
could be used for FIV diagnostic or prognostic purposes, as well as to distinguish FIV-positive 
from vaccinated cats.  In order to use the FIV-specific IgG MIA as a diagnostic assay, 
experiments would need to be conducted to demonstrate that the MIA has equivalent specificity 
and sensitivity to the current serodiagnostic assay (SNAP FIV antibody/FeLV antigen combo 
test, IDEXX Laboratories).  Using MIAs, the presence/absence of particular cytokines or 
antibodies in domestic cat plasma/serum could be used to predict disease outcome.  With HIV 
patients, for example, low initial titers or a decline in α-CA antibodies correlate with a faster rate 
of disease progression (3, 7, 19); increasing levels of serum IL-10 are associated with disease 
progression (15); and higher plasma concentrations of IL-1α and IL-7 correlate with an increased 
risk of CD4
+ 
T-cell loss (10).  Additionally, a MIA could be developed to differentiate infected 
and vaccinated animals by multiplexing the two enzyme-linked immunosorbent assays currently 
used for differentiation (TM peptide and formalin-treated FIV capture antigens; (8)).  
Alternatively, given that the FIV vaccine contains inactivated whole virus from clades A and D 
((9); Fel-O-Vax FIV, Fort Dodge Animal Health), it might be possible to develop a MIA to 
detect antibodies specific to the formalin-treated viruses used in the vaccine.  Detectable 
antibodies to both clade A and D formalin-treated virus/viral proteins would suggest that the cat 
had been vaccinated versus naturally infected.   
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As demonstrated in this dissertation, these newly developed feline-specific assays will be 
useful to evaluate the immune response of domestic cats infected with FIV (in addition to 
previously used assays), or to evaluate viral RNA levels of wild felids naturally infected with 
FIV.  By validating each of the domestic cat MIAs (according to published guidelines), we 
demonstrated the accuracy and precision of the assays, and established a lower limit of 
quantitation (LLOQ).  Equivalent validation experiments will also be conducted for the 
quantitative PCR assays once development is complete.  Although data from non-validated 
assays are useful for determining whether an analyte of interest is detectable, the reported values 
lack accuracy/confidence.  By validating the new assays, as described here, we demonstrated the 
method repeatability and LLOQ, and thus provided confidence in the values reported for samples 
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